

RSC Medicinal Chemistry

rsc.li/medchem



ISSN 2632-8682

RESEARCH ARTICLE

Milan Kožíšek, Aleš Machara *et al.*
Beyond natural flavonoids: exploring bioisosterism in design
and synthesis of influenza endonuclease inhibitors

Cite this: *RSC Med. Chem.*, 2025, 16, 3030

Beyond natural flavonoids: exploring bioisosterism in design and synthesis of influenza endonuclease inhibitors†

Róbert Reiberger,^{ab} Michal Král,^{ac} Kateřina Radilová,^a Tomáš Kotačka,^{ac} Martin Dračinský,^a Artem Tsalya,^a Jiří Brynda,^{ae} Pavel Majer,^a Jan Konvalinka,^{ad} Milan Kožíšek^{*a} and Aleš Machara^{id}^{*a}

Influenza virus, an RNA virus of the *Orthomyxoviridae* family, is responsible for widespread seasonal epidemics that result in 3 to 5 million severe illnesses and more than half a million deaths annually. Given the persistent circulation of pandemic influenza variants and increasing resistance to available inhibitors, there is an urgent need for new antiviral drugs effective against various viral subtypes. Viral RNA-dependent RNA polymerase, essential for viral replication, has emerged as a promising drug target. The PA subunit with endonuclease function is especially interesting, as development of the highly potent baloxavir marboxil (Xofluza) validated its importance as a novel drug target. Flavonoids have long been studied for their anti-influenza activity but have only recently been recognized as endonuclease inhibitors. We previously identified luteolin and its glucoside derivative, orientin, as potent endonuclease inhibitors, with their binding illustrated by X-ray crystallography structures. Building on this, we employed a scaffold-hopping approach based on the luteolin structure to design structurally distinct compounds that resemble the flavonoid scaffold. Using an AlphaScreen binding assay, we identified **33** as a submicromolar PA inhibitor with low toxicity. We solved the crystal structure of the PA endonuclease-binding pseudoflavonoid **36**, which has similar structure and inhibitory potency to **33**. Furthermore, we identified **24**, **33**, **34** and **36** as inhibitors of influenza polymerase in a minireplicon luciferase reporter assay as well as inhibitors of live H1N1 virus infection in A549 human lung cells.

Received 22nd January 2025,
Accepted 3rd March 2025

DOI: 10.1039/d5md00071h

rsc.li/medchem

1 Introduction

Influenza A virus (IAV) remains a major public health concern due to its high virulence and rapid mutation rate, which have contributed to several human influenza pandemics over the past century. Despite substantial efforts to develop and disseminate vaccines, seasonal influenza epidemics result in millions of severe cases and hundreds of thousands of deaths worldwide annually.¹

Antiviral drugs are the primary treatment for influenza infections. In recent years, antiviral compounds targeting RNA-dependent RNA polymerase^{2–5} (RdRp) have demonstrated acceptable efficacy, while viral mutations have diminished the effectiveness of neuraminidase inhibitors and M2 protein blockers. Influenza viruses contain a single-stranded, negative-sense RNA genome complexed with RdRp, which comprises PA, PB1, and PB2 subunits.^{2,6} The virus cannot synthesize the 5'-mRNA cap necessary for eukaryotic translation, representing a significant vulnerability and a target for drug development.^{4,7} The virus acquires host primers required for transcription initiation through a “cap-snatching” mechanism.⁸ This begins when the PB2 subunit binds to the 5'-cap (m7GTP) of host pre-mRNA. Next, the PA subunit cleaves the RNA strand approximately 10–13 nucleotides downstream from the 5'-cap to obtain the primer.^{9,10} The PB1 subunit subsequently uses this primer as a template for viral mRNA synthesis. Notably, RdRp, particularly the PA domain, is highly conserved across influenza strains, making it an attractive target for drug

^a Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic.

E-mail: milan.kozisek@uochb.cas.cz, machara@uochb.cas.cz

^b Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 00, Prague 2, Czech Republic

^c First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic

^d Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 128 00, Prague 2, Czech Republic

^e Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 140 00, Prague 4, Czech Republic

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5md00071h>



development.^{4,11–13} Research on inhibitors targeting all three subunits involved in the cap-snatching mechanism has been prolific.^{3,7}

The PA subunit of influenza RdRp is a bridged binuclear metalloenzyme,¹⁴ with its N-terminal domain (PA-Nter) housing the endonuclease active site responsible for cleaving RNA segments.¹⁰ This active site is a negatively charged pocket that binds two Mg²⁺ or Mn²⁺ ions, with a stronger affinity for Mn²⁺.¹⁵ These ions are crucial for endonuclease function, and an inhibitor designed to target this site must include a metal-binding pharmacophore^{14,16} capable of binding Mg²⁺/Mn²⁺ ions efficiently.^{17,18} The most successful PA inhibitor to date is baloxavir marboxil (BMX),^{19,20} which was developed by Roche and Shionogi and has received regulatory approval in the USA and Japan. Although baloxavir marboxil showed favorable efficacy in clinical studies, recent studies indicate that influenza virus can develop resistance against baloxavir through I38T/M/F mutations in PA.^{21–23} This highlights the need for the development of new anti-influenza drugs that target endonuclease using a novel metal-binding pharmacophore. Approximately a dozen classes of PA-Nter endonuclease inhibitors have been documented, including diketo acids,²⁴ dopamine derivatives,^{25,26} hydroxylated heterocycles,^{27–32} green tea catechins,^{33,34} flutamide derivatives,³⁵ catechol congeners,³⁶ 2,3-dihydroisoindole derivatives,³⁷ carbamoyl pyridone derivatives,^{29,38,39} hydroxylated *N*-acylhydrazones⁴⁰ and others.⁴¹ In 2020, we elucidated the molecular mode of action of flavonoids in influenza-infected cells.⁴² Using an AlphaScreen-based assay, we determined the inhibitory potencies of more than 30 flavonoids, identifying luteolin (Fig. 1, IC₅₀ = 73 ± 3 nM) and its 8-*C*-glucoside orientin (IC₅₀ = 42 ± 2 nM) as the most potent PA inhibitors. These results were corroborated by a gel-based endonuclease inhibitory assay. Furthermore, we performed structural analyses of PA-Nter complexes with luteolin and orientin, detailing their binding poses within the PA-Nter active site.^{42,43} The crystal structure of the PA-Nter complex with luteolin (PDB entry 6YA5, 2.0 Å resolution) revealed that the phenolic group at the C-7 position forms a hydrogen bond with the Glu-26 residue of PA-Nter (Fig. 1). The Mn²⁺ cation is coordinated by the atoms of the protein residues His-41, Asp-108, Glu-119, O Ile-120, and the catechol moiety of luteolin (3',4'-dihydroxyphenyl moiety; see blue residue in Fig. 1). The Mg²⁺ cation is coordinated by Glu-80, Asp-108, the C-3' phenolic group of luteolin, and three water molecules. The high affinity of luteolin can be attributed to surface complementarity and a strong hydrogen bonding network, evidenced by the well-defined electron density map of luteolin in the crystal structure.

Our structure–activity relationship (SAR) study indicated that the 3',4'-dihydroxyflavone motif is crucial for inhibitory activity against PA.⁴² The presence of phenolic groups at the C-5 and C-7 positions significantly enhanced anti-influenza activity. Additionally, we observed that the corresponding aza-analogues, such as azaluteolin (Fig. 1), exhibited similar half-maximal inhibitory concentrations.

Over the past decades, it has become evident that there are significant differences between the biological properties of flavonoids observed *in vitro* and their bioactivity *in vivo*. Flavonoids exhibit two primary drawbacks for drug development. First, they are classified as pan-assay interference compounds (PAINS),^{44,45} meaning their polyphenolic structure frequently leads to false positives across a variety of biochemical assays. This chemical promiscuity must always be considered. Nonetheless, in our prior research, two different biochemical assays confirmed that flavonoids can inhibit PA.^{46,47} Moreover, X-ray crystallography of the luteolin–PA-Nter complex clearly revealed that it binds to the endonuclease active site. The second drawback is that flavonoids have limited bioavailability.^{48–50} The *in vivo* biological activity of flavonoids is clearly compromised by their poor bioavailability due to facile modifications like oxidation, glucuronylation or sulfation. This study outlines a rational design approach for influenza endonuclease inhibitors derived from the luteolin structure, aiming to pave the way for more effective *in cellulo* inhibitors. Specifically, we detail our medicinal chemistry efforts to develop a series of pseudoflavonoids using a scaffold-hopping strategy.

Over the past decades, it has become evident that there are significant differences between the biological properties of flavonoids observed *in vitro* and their bioactivity *in vivo*. Flavonoids exhibit two primary drawbacks for drug development. First, they are classified as pan-assay interference compounds (PAINS),^{44,45} meaning their polyphenolic structure frequently leads to false positives across a variety of biochemical assays. This chemical promiscuity must always be considered. Nonetheless, in our prior research, two different biochemical assays confirmed that flavonoids can inhibit PA.^{46,47} Moreover, X-ray crystallography of the luteolin–PA-Nter complex clearly revealed that it binds to the endonuclease active site. The second drawback is that flavonoids have limited bioavailability.^{48–50} The *in vivo* biological activity of flavonoids is clearly compromised by their poor bioavailability due to facile modifications like oxidation, glucuronylation or sulfation. This study outlines a rational design approach for influenza endonuclease inhibitors derived from the luteolin structure, aiming to pave the way for more effective *in cellulo* inhibitors. Specifically, we detail our medicinal chemistry efforts to develop a series of pseudoflavonoids using a scaffold-hopping strategy.

2 Results and discussion

2.1 Scaffold-hopping approach generates a series of pseudoflavonoids

To optimize the central core of luteolin using a scaffold-hopping approach,⁵¹ we had to examine the significance




Fig. 1 Flavonoid inhibitors of influenza endonuclease and graphical illustration of the binding mode of luteolin in the PA-Nter active site.






Scheme 1 Reagents and reaction conditions: (i) MeI, K₂CO₃, DMF, r.t., 24 h; (ii) (2,2-dimethylbenzo[d][1,3]dioxol-5-yl)boronic acid, SPhos Pd G2 (10 mol%), K₂CO₃, THF/H₂O (25:1), 100 °C, 16 h; (iii) BBr₃, DCM, 0 °C → r.t., 1 h; (iv) BBr₃, DCM, -78 °C → r.t.

of individual hydroxy groups within the polyphenol structure. Initially, our attention was drawn to the simplest derivative 4 (Scheme 1), whose structure retains only the most essential OH group on the central naphthalene core. In luteolin, this C-7 phenolic group interacts with Glu-26 of the PA subunit.⁴⁶ To synthesize 4 (depicted in Scheme 1), bromonaphthol 1 was methylated according to Kawara's protocol⁵² in high yield. Subsequent C–C cross-coupling using a Buchwald precatalyst gave benzodioxole 3 in 96% yield. A similarly high yield of Pd-

catalyzed coupling was achieved in the synthesis of quinoline derivative 6 starting with dimethoxychloroquinoline 5. Treatment of 3 and 6 under standard *O*-demethylation conditions⁵³ using boron tribromide afforded derivatives 4 and 7, respectively, in yields of around 65%.

Compounds 10 and 14, key intermediates for synthesis of isomeric tetraols 12 and 17, were prepared following protocols described in the literature^{54–56} (Scheme 2). Miyaura–Ishiyama–Hartwig borylations⁵⁷ of 10 and 14 using C–H bond activation provided boronates 11 and 15



Scheme 2 Reagents and reaction conditions: (i) 4 M HCl (1,4-dioxane), MeOH, 0 °C → r.t., 24 h; (ii) TBDMSCl, imidazole, THF, 0 °C → r.t., 16 h; (iii) B₂(pin)₂, [Ir(COD)OMe]₂ (4 mol%), bbbpy (6 mol%), *n*-hexane, 100 °C, 16–72 h; (iv) 4-bromoveratrole, SPhos Pd G2 (10 mol%), K₂CO₃, THF/H₂O (25:1), 100 °C, 16 h; (v) TBAF, THF, 0 °C, 2 h; (vi) BBr₃, DCM, 0 °C → r.t., 2 h; (vii) MeI, K₂CO₃, DMF, r.t., 18 h.




in acceptable yields ranging from 52% to 96%. However, high regioselectivity of borylation was achieved only for boronate **15**. Despite the introduction of a bulky TBDMS group on the C-1 hydroxy group of **10**, we were able to isolate only an inseparable mixture of regioisomers **11a** and **11b** in a roughly 2:1 ratio. Therefore, we used a pre-purified mixture of boronates **11a,b** in a subsequent Suzuki–Miyaura cross-coupling reaction, again yielding an inseparable mixture of isomers. This mixture was deprotected in a two-step sequence using TBAF for desilylation and BBr_3 for double *O*-demethylation. The pure product **12** was isolated after repeated preparative HPLC in an overall 15% yield (over 3 steps). Preparation of **17** was accomplished analogously (Scheme 2). Both the cross-coupling leading to **16** and the subsequent *O*-demethylation affording C-3 arylated 1,6-dihydroxynaphthalene **17** provided corresponding products in moderate yields.

Having naphthol **4**, quinolone derivative **7**, and dihydroxynaphthalene derivatives **12** and **17** on hand, our interest shifted to preparation of a trihydroxynaphthalene derivative with three hydroxy groups aligned topologically as in luteolin. In theory, we expected 6-(3,4-dihydroxyphenyl) naphthalene-1,3,8-triol (**24**) to form interactions within the PA-Nter active site comparable to those of luteolin. We thus considered **24** as a prime candidate for the scaffold-hopping approach. Following a modified Cameron's approach,⁵⁸ linear synthesis of **24** began with Stobbe condensation of 3,5-dimethoxybenzaldehyde and dimethyl succinate under strongly basic conditions (Scheme 3). 6-*Exo-trig* cyclization of the crude intermediate with acetic anhydride and potassium acetate resulted in formation of ester **19**. Next, acid **20** was obtained through saponification. A subsequent domino methylation/saponification reaction in DMF


containing a trace amount of water provided acid **21** in 66% yield. Catalytic decarbonylative borylation of **21** by the Szostak protocol⁵⁹ afforded boronate **22** in 55% yield. The synthesis of carboluteolin (**24**) was subsequently accomplished using a similar reaction sequence to that of the dihydroxynaphthalene derivative **17**.

Building on this foundation, we designed and synthesized a series of compounds in which azacyclic metal-binding pharmacophores are attached to the 1,3,8-trihydroxynaphthalene core, thus replacing the metabolically labile 3',4'-dihydroxyphenyl (catechol) moiety of the parent luteolin structure. We hypothesize that these azacyclic derivatives, which are likely metabolized *via* distinct pathways compared to the catechol moiety, could demonstrate enhanced antiviral activity in tissue culture. Boronate **22** was subjected to Suzuki–Miyaura cross-coupling with the corresponding heteroaryl halides (Scheme 4). Optimization of the catalytic systems indicated that $\text{Pd}(\text{PPh}_3)_4$ was a more efficient option than Buchwald precatalysts. Surprisingly, these palladacycle-based catalysts initially provided **25** in yields up to only 25%. On the other hand, the $\text{Pd}(\text{PPh}_3)_4$ catalyst led to the preparation of C-6 substituted per-*O*-methylated naphthalentriols **25–30** in yields of 37–98%. A standard one-step *O*-demethylation using BBr_3 was successful only for pyridine derivatives **25–27**. Due to the lower reactivity of **28–30** towards BBr_3 , a procedure described by Sagong⁶⁰ was employed. Although BBr_3 was used in the first step, after evaporation of the reaction mixture, the crude product was further combined with 4 M hydrogen chloride in 1,4-dioxane at elevated temperature. This approach yielded pseudoflavonoids **31–36** containing azacycle moieties with yields varying from 14% to 53%.



Scheme 3 Reagents and reaction conditions: (i) dimethyl succinate, *t*-BuOK, *t*-BuOH, 90 °C, 3 h; (ii) Ac_2O , KOAc, 145 °C, 6 h; (iii) 2.5 M NaOH (aq.), H_2O , 100 °C, 1 h; (iv) MeI, NaH, benzyltriethylammonium chloride, DMF, 25 °C; 3 d; (v) $\text{B}_2(\text{pin})_2$, $\text{Pd}(\text{OAc})_2$ (5 mol%), dppb (10 mol%), Et_3N , Piv_2O , 1,4-dioxane, 160 °C, 15 h; (vi) 5-bromo-2,2-dimethylbenzo[d][1,3]dioxole, SPhos Pd G2 (10 mol%), K_2CO_3 , THF/ H_2O (25:1), 100 °C, 2 h; (vii) BBr_3 , DCM, 0 °C → r.t., 2 h.





Scheme 4 Reagents and reaction conditions: (i) heteroarylhalide (39/40/41/43/44/45), Pd(PPh₃)₄ (10 mol%), K₂CO₃, 1,4-dioxane/H₂O (3 : 1), 100 °C, 16 h; (ii) BBr₃, DCM, 0 °C → r.t., 48 h; (iii) (a) BBr₃, DCM, 0 °C → r.t., 6–24 h; (b) 4 M HCl (1,4-dioxane), 1,4-dioxane, 110 °C, 16 h, 5–24 h.

Table 1 Inhibition assay of influenza endonuclease. Structure–activity relationship of polyphenol derivatives

Compound	Structure	IC ₅₀ ± SD (μM) (AlphaScreen)
Luteolin		0.073 ± 0.003
4		22 ± 4
7		8.1 ± 0.8
12		7.7 ± 0.4
17		3.9 ± 1.2
24		0.38 ± 0.06

2.2 AlphaScreen highlights the importance of the trihydroxynaphthalene core and enables selection of lead compounds

We first assessed the inhibitory potencies of the synthesized compounds using an AlphaScreen binding assay.^{46,61} Our initial SAR study aimed to identify the hydroxy groups on the naphthalene and quinoline scaffolds that are essential for optimal inhibitory potency (Table 1). The parent compound luteolin inhibited endonuclease with an IC₅₀ of 0.073 μM. Compound 4, which bears a single phenolic group on the central core, exhibited an approximately two-orders-of-

magnitude weaker inhibitory potency (IC₅₀ = 22 μM). Structurally similar derivatives 7 and 12 had greater potency than 4 (IC₅₀ = 8.1 and 7.7 μM, respectively), highlighting the positive impact of two hydroxy groups at C-5 and C-7 (flavonoid numbering) on inhibitory potency. Compound 17, a structural isomer of 12 that retains the phenolic group at C-7 but has a second phenolic group at C-4, proved to be a superior inhibitor compared to 12. Compound 24 exhibited an IC₅₀ of 0.38 μM, indicating that a specific trihydroxynaphthalene core is necessary for submicromolar inhibitory potency. Furthermore, its fivefold higher IC₅₀ value



Table 2 Inhibition assay of influenza endonuclease. Structure–activity relationship of pseudoflavonoids

Compound	Structure	IC ₅₀ ± SD (μM) (AlphaScreen)
Luteolin		0.073 ± 0.003
Azaluteolin		0.068 ± 0.002
24 (carboluteolin)		0.38 ± 0.06
31		8.8 ± 0.6
32		4.3 ± 0.4
33		0.79 ± 0.1
34		3.3 ± 0.1
35		12 ± 2
36		1.7 ± 0.3

compared to that of luteolin suggests that, despite having similar footprints, luteolin and **24** slightly differ in their binding interactions with the endonuclease active site.

Having identified the minimal number of phenolic groups on the naphthalene core required for submicromolar inhibitory potency, we proceeded to investigate carboluteolin analogues with hydroxylated azacycles replacing the metabolically vulnerable 3',4'-dihydroxyphenyl motif (Table 2). Isomeric compounds **31** and **32**, containing 3-hydroxypyridin-2(1*H*)-one-5-yl⁶² and 3-hydroxypyridin-2(1*H*)-one-6-yl⁶² moieties, had lower inhibitory potencies than **24**, with IC₅₀ values greater than 4 μM. Conversely, **33**, which features a 5-hydroxypyridine-4(1*H*)-one-2-yl metal-binding pharmacophore,¹⁸ demonstrated submicromolar inhibitory potency. Derivatives **34** and **35**, with 3-hydroxypyrazin-2(1*H*)-one-6-yl⁶⁰ and 4-hydroxypyridazin-3(2*H*)-6-yl⁶⁰ moieties,

respectively, displayed reduced inhibitory potencies, with IC₅₀ values of 3.3 and 12 μM. The IC₅₀ value determined for **36** was between those of **33** and **32**, reflecting the structural similarities between hydroxypyridinone and hydroxypyrimidinone⁶⁰ moieties. Based on the results of this SAR analysis, we selected compounds **24**, **33**, **34** and **36** for further evaluation.

2.3 Pseudoflavonoids inhibit endonuclease and exhibit antiviral activity in cell-based assays

Based on the good performance of **24**, **33**, **34** and **36** in the AlphaScreen binding assay, we further characterized their inhibitory potency using two approaches: (i) a minireplicon (or minigenome) luciferase reporter assay based on transfection of plasmids encoding active influenza A



Table 3 Antiviral activity in cell-based assays

Compound	EC ₅₀ minireplicon (μM)		EC ₅₀ antiviral testing (μM)		CC ₅₀ cytotoxicity (μM)		
	HEK 293T	A549	MDCK	A549	HEK 293T	A549	MDCK
24	1.1 ± 0.1	0.8 ± 0.2	>100	12 ± 1	>50	>50	>50
33	2.1 ± 0.2	2.8 ± 0.6	41 ± 13	2.4 ± 0.4	>50	>50	>50
34	1.8 ± 0.1	1.7 ± 0.4	>100	>100	>50	>50	>50
36	1.4 ± 0.2	1.8 ± 0.5	>100	10 ± 1	>50	>50	>50
Luteolin	>100	9.2 ± 4.1	>100	20 ± 2	>50	>50	>50
BMX	0.002 ± 0.0006	0.004 ± 0.001	0.030 ± 0.008	1.8 ± 0.4	>50	>50	>50
BXA	n.d.	n.d.	0.070 ± 0.017	0.093 ± 0.013	n.d.	14 ± 3	5 ± 1

polymerase into cells and (ii) a cytopathic effect reduction assay using infectious influenza H1N1 virus. First, we employed the minigenome strategy; all four selected compounds showed promising inhibition in transfected HEK 293T cells, with IC₅₀ values in the low micromolar range (1.1–2.1 μM, Table 3). The parent compound luteolin did not show any inhibition of influenza A polymerase.

We next tested the compounds in a cytopathic effect reduction assay using Madin–Darby canine kidney (MDCK) cells, which are generally used for anti-influenza inhibitor testing. However, luteolin and all the selected compounds except **33** (EC₅₀ = 41 ± 13 μM) exhibited very poor or no activity (EC₅₀ >100 μM). This effect is likely due to the poor permeability of MDCK cells to the tested compounds, as our control compound, baloxavir marboxil, was able to stop the infection in its usual concentration range (EC₅₀ = 0.030 ± 0.008 μM). To overcome this, we switched from MDCK cells to A549 cells, human lung adenocarcinoma cells that are susceptible to influenza virus infection. Using A549 cells, we were able to determine the inhibitory potencies of **24** (EC₅₀ = 12 ± 1 μM), **33** (EC₅₀ = 2.4 ± 0.4 μM) and **36** (EC₅₀ = 10 ± 1 μM). Interestingly, although luteolin did not exhibit any antiviral activity in MDCK cells, it had a weak effect in A549 cells (EC₅₀ = 20 ± 2 μM). The control compound, baloxavir marboxil, exhibited markedly decreased inhibitory potency in A549 cells (EC₅₀ = 1.8 ± 0.4 μM) compared to MDCK cells. As an additional control, we used baloxavir acid, the active form of baloxavir marboxil. Interestingly, it retained its inhibitory potency in nanomolar range in both A549 and MDCK cells. This active form exhibited moderate cytotoxicity, which was, however, well outside of the inhibitory range.

2.4 X-ray crystallography reveals details of pseudoflavonoid binding to influenza endonuclease

To confirm the binding of pseudoflavonoids in the active site of PA-Nter, we selected **36** (IC₅₀ = 1.7 ± 0.3 μM) to be soaked into empty protein crystals, as the most active compound, **33**, had not yet been synthesized at the time. The structure of PA-Nter in complex with **36** (PDB ligand 8PPX) was refined to 2.5 Å. Each asymmetric unit consisted of one PA-Nter molecule. In alignment with earlier PA-Nter structures,³³ two octahedrally coordinated metal ions were present in the active site (Fig. 2). The distal magnesium ion with a weaker

anomalous signal was coordinated by O^{ε2} Glu-80, O^δ Asp-108, three water molecules (w1, w2, w3), and the C-5' hydroxy group of **36**. The proximal site was fully occupied by the manganese ion with a strong anomalous signal (up to 2.75 Å). The manganese ion lies in the center of an octahedral coordination sphere including four protein atoms (N^{ε2} His-41, O^{ε2} Asp-108, O^{ε2} Glu 119, O Ile-120) and the C-5' hydroxy and C-4' keto groups of **36**.

Compound **36** binds in the PA-Nter domain active site⁴⁶ with a similar coordination pattern to that of luteolin. Like luteolin, one hydroxy and one keto group of the hydroxypyrimidinone moiety of **36** chelate the manganese ion. However, the positions of the C-5' hydroxy and C-4' keto groups of **36** are rotated by 180 degrees relative to luteolin's hydroxy groups, resulting in a distinct orientation of the central naphthalene core of **36** within the PA-Nter active site. Structural superposition of **36** and luteolin gave an RMSD of 4.2 Å for nineteen corresponding atoms. Additionally, the C-7 hydroxy group (luteolin numbering) of **36** formed a hydrogen bond with Arg-134; in the PA-Nter-luteolin complex; this interaction occurs with O^{ε2} Glu-26 (Fig. 3). The C-5 hydroxy group of **36** also formed an interaction with N^ε Lys-34.




Fig. 2 Close-up view of PA-Nter with bound ligand **36** (PDB entry 8PPX). Metal ions (left – manganese, right – magnesium) are shown as purple-blue spheres. Compound **36** (in cyan stick representation) coordinates the manganese ion with its C-5' hydroxy and C-4' keto moieties. The hydroxy group at C-7 (flavonoid numbering) of **36** forms a hydrogen bond with N^{η2} Arg-124, and the C-5 hydroxy group with N^ε Lys-34. The ligand electron density map (blue mesh) is contoured at 1.5σ, and the electron density for anomalous scattering (white mesh) is contoured at 5σ. Interacting side chains of PA-Nter are shown as blue sticks. Other color coding: oxygen – red, nitrogen – dark blue.






Fig. 3 Alignment of PA-Nter in complex with **36** (cyan, PDB entry 8PPX) and luteolin (yellow, PDB entry 6YA5). Both **36** and luteolin coordinate metal ions in the protein active site via hydroxylated (hetero)aryl moieties (hydroxypyrimidone and 3',4'-dihydroxyphenyl moieties, respectively). In the case of luteolin, the C-7 hydroxy group forms a hydrogen bond with O^{δ2} Glu-26. This represents a distinct binding mode compared to that of **36**, in which the 3',4'-dihydroxyphenyl moiety is rotated by approximately 180 degrees, resulting in the C-7 hydroxy group interacting with the side chain of Arg-124. PA-Nter is in cartoon representation with interacting side chains shown as sticks. Color coding: oxygen – red, nitrogen – dark blue, carbon atoms of protein – blue (PA-Nter/**36**) and yellow (PA-Nter/luteolin).

3 Conclusions

We report the synthesis and biochemical evaluation of a series of luteolin bioisosteres. These unprecedented compounds, named “pseudoflavonoids”, were designed as inhibitors of influenza endonuclease. Applying a scaffold-hopping approach involving replacement of 3',4'-dihydroxyphenyl with hydroxylated azacycles, we obtained a few compounds with moderate in-cell activity. Optimizing the topology of the hydroxypyridinone moiety serving as a metal-binding pharmacophore led to discovery of **33**, which exhibited submicromolar inhibitory potency. The scaffold-hopping approach furnished compounds that exhibited increased inhibitory potencies in cells (minireplicon and cytopathic effect reduction assays) compared to luteolin. Interestingly, commonly used MDCK cells proved to be unsuitable for testing of these compounds, possibly due to their poor cellular permeability. However, we were able to establish the inhibitory effect of our compounds (**24**, **33**, **34** and **36**) in human lung A549 cells and confirm it with a luciferase reporter assay. In a cytopathic effect reduction assay using the infectious influenza H1N1 virus and human lung adenocarcinoma cells, compound **33** demonstrated a comparable inhibitory potency to baloxavir marboxil, which is currently used in clinical practice ($EC_{50} = 2.4 \pm 0.4 \mu\text{M}$ versus $EC_{50} = 1.8 \pm 0.4 \mu\text{M}$). Through X-ray crystallography structural analysis, we elucidated similarities and differences in the binding motif of **36** compared to luteolin. The “pseudoflavonoids” described here share a relatively high structural similarity with flavonoids, particularly due to the presence of phenolic groups. Nevertheless, these compounds represent important stepping stones toward the design of

flavonoid bioisosteres with significantly improved properties enabling them to be used for the treatment of important human diseases.

4 Experimental section

4.1 Chemistry

Unless otherwise noted, all reactions were carried out under argon in oven-dried glassware. Anhydrous solvents were distilled from solvents using the indicated agents and transferred under nitrogen: THF (Na/benzophenone), toluene (Na/benzophenone), MeCN (CaH₂), and DCM (CaH₂). Chromatography was performed using a Teledyne ISCO CombiFlash NextGen 300+ flash chromatography system with RediSep Rf Gold Silica or RediSep (marked as SiO₂) Rf Gold Reversed-phase C18 columns (marked SiO₂-C₁₈ or SiO₂-C₁₈-Aq). All starting materials were used as purchased (Merck, Alfa Aesar, TCI, Fluorochem, Combi-Blocks) unless otherwise indicated. All inhibitors were purified using an ECOM compact preparative system TOY18DAD800 (flow rate 15 mL min⁻¹; gradient 0 → 60% or 0 → 80% H₂O (0.1% trifluoroacetic acid)/MeCN in 60 min) with a ProntoSIL 120-10-C18 ace-EPS column, 10 μm, 20 × 250 mm. The purity of compounds and composition of the reaction mixtures were tested on a Waters UPLC-MS ACQUITY system with a QDa Mass Detector (flow rate 0.5 mL min⁻¹, gradient 0 → 100% H₂O (0.1% formic acid)/MeCN in 7 min) and an ACQUITY UPLC BEH C18 Column, 130 Å, 1.7 μm, 2.1 mm × 100 mm with a 2.1 mm × 5 mm pre-column. The final inhibitors were of at least 95% purity. ¹H NMR spectra were recorded on Bruker instruments at 401, 500 or 600 MHz; ¹³C NMR spectra were recorded at 101, 126 or 151 MHz. Chemical shifts are provided in δ-scale in ppm; coupling constants (*J*) are given in Hz. Signals marked with an asterisk (*) were visible in two-dimensional NMR spectra (HMBC). FT-IR spectra were recorded using a Nicolet iS50 spectrophotometer. Wavenumbers are provided in $\tilde{\nu}$ -scale in cm⁻¹. ESI or APCI high-resolution mass spectra were recorded using a Thermo Scientific LTQ Orbitrap XL spectrometer (Thermo Fisher Scientific) and EI or CI high-resolution mass spectra were recorded using an Agilent 7250 GC/Q-TOF system, both controlled by MassLynx software.

4.1.1 Inhibitor synthesis

2-Bromo-7-methoxynaphthalene (2). 7-Bromonaphthalen-2-ol (**1**) (500 mg, 2.24 mmol, 1.0 eq.) was dissolved in DMF (10 mL), followed by addition of K₂CO₃ (928 mg, 6.72 mmol, 3.0 eq.) and iodomethane (1.05 mL, 16.8 mmol, 7.5 eq.). The reaction mixture was allowed to stir at room temperature overnight until the starting material was consumed (TLC, UPLC-MS). The mixture was quenched with saturated NH₄Cl (2.0 mL) followed by addition of EtOAc (15 mL). The organic phase was washed with water (3 × 20 mL) and brine (1 × 10 mL) and dried over anhydrous MgSO₄. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, *n*-hexane/EtOAc = 100 → 90:10) to



afford the desired compound **2** (435 mg, 82%). ^1H NMR (401 MHz, CDCl_3) δ = 7.90 (dd, J = 2.0, 0.7 Hz, 1H), 7.69 (dd, J = 8.9, 0.7 Hz, 1H), 7.66–7.57 (m, 1H), 7.41 (dd, J = 8.7, 2.0 Hz, 1H), 7.15 (dd, J = 9.0, 2.5 Hz, 1H), 7.02 (d, J = 2.5 Hz, 1H), 3.91 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 158.5, 135.9, 129.5, 129.4, 128.8, 127.4, 127.0, 120.7, 119.3, 105.0, 55.5 ppm. LRMS (APCI) m/z calcd for $\text{C}_{11}\text{H}_{10}\text{BrO}$ [$\text{M} + \text{H}^+$] $^+$ 236.99, found 236.46.

5-(7-Methoxynaphthalen-2-yl)-2,2-dimethylbenzo[d][1,3]dioxole (3). A tube with 2-bromo-7-methoxynaphthalene (**2**) (100 mg, 0.42 mmol, 1.0 eq.), (2,2-dimethylbenzo[d][1,3]dioxol-5-yl)boronic acid (123 mg, 0.63 mmol, 1.5 eq.), K_2CO_3 (232 mg, 1.68 mmol, 4.0 eq.) and SPhos Pd G2 (30 mg, 0.042 mmol, 0.1 eq.) was sealed and THF/water (25 : 1, 5.3 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes, followed by heating to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). The reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO_2 , *n*-hexane/EtOAc = 100 : 0 \rightarrow 85 : 15) to afford the desired product **3** (123 mg, 96%). ^1H NMR (401 MHz, CDCl_3) δ = 7.86 (d, J = 1.8 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.53 (dd, J = 8.5, 1.8 Hz, 1H), 7.21–7.09 (m, 4H), 6.85 (d, J = 8.0 Hz, 1H), 3.95 (s, 3H), 1.74 (s, 6H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 158.1, 148.1, 147.1, 139.2, 135.1, 135.0, 129.2, 128.2, 128.0, 124.3, 123.4, 120.4, 118.6, 118.3, 108.6, 107.8, 106.0, 55.4, 53.5, 26.0 ppm. HRMS (APCI) m/z calcd for $\text{C}_{20}\text{H}_{19}\text{O}_3$ [$\text{M} + \text{H}^+$] $^+$ 307.1329, found 307.1329.

4-(7-Hydroxynaphthalen-2-yl)benzene-1,2-diol (4). Compound **3** (123 mg, 0.4 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (1.4 mL). The solution was cooled to 0 °C in an ice water bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (3 mL, 3.0 mmol, 7.5 eq.) was added dropwise under a nitrogen atmosphere. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 1 hour at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). After 30 minutes of stirring, the resulting white suspension was extracted with EtOAc (3 \times 20 mL). The combined organic phases were dried over anhydrous MgSO_4 . The solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product **4** (71 mg, 70%). ^1H NMR (401 MHz, $\text{DMSO}-d_6$) δ = 9.70 (s, 1H), 9.11–9.05 (m, 1H), 9.05–9.01 (m, 1H), 7.88–7.70 (m, 3H), 7.46 (dd, J = 8.5, 1.8 Hz, 1H), 7.16 (d, J = 2.2 Hz, 2H), 7.04 (ddd, J = 8.8, 7.5, 2.3 Hz, 2H), 6.85 (d, J = 8.2 Hz, 1H) ppm. ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ = 155.6, 145.6, 145.2, 138.0, 135.0, 131.7, 129.0, 128.0, 126.5, 122.3, 121.7, 118.2, 118.0, 116.1, 114.2, 108.9 ppm. HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{11}\text{O}_3$ [$\text{M}-\text{H}^+$] $^-$ 251.0714, found 251.0713.

2-(2,2-Dimethylbenzo[d][1,3]dioxol-5-yl)-5,7-dimethoxyquinoline (6). A tube with 2-chloro-5,7-dimethoxyquinoline (**5**) (100 mg, 0.44 mmol, 1.0 eq.), (2,2-dimethylbenzo[d][1,3]dioxol-5-yl)boronic acid (133 mg, 0.67 mmol, 1.5 eq.), K_2CO_3 (243 mg, 1.76 mmol, 4.0 eq.) and SPhos Pd G2 (32 mg, 0.044 mmol, 0.1 eq.) was

sealed and THF/water (25 : 1, 5.5 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes, followed by heating to 100 °C for 3 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO_2 , *n*-hexane/EtOAc = 100 : 0 \rightarrow 80 : 20) to afford the desired product **6** (149 mg, 98%). ^1H NMR (401 MHz, CDCl_3) δ = 8.39 (dd, J = 8.7, 0.7 Hz, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.58–7.53 (m, 2H), 7.05 (dd, J = 2.2, 0.7 Hz, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.45 (d, J = 2.2 Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 1.71 (s, 6H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 161.4, 157.8, 156.0, 150.3, 148.6, 148.2, 133.7, 131.3, 121.2, 118.4, 115.6, 115.2, 108.3, 107.8, 99.9, 97.6, 55.7, 55.6, 25.9 ppm. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{O}_4\text{N}$ [$\text{M} + \text{H}^+$] $^+$ 338.1387, found 338.1386.

2-(3,4-Dihydroxyphenyl)quinoline-5,7-diol (7). Quinoline **6** (140 mg, 0.41 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (1.4 mL). The solution was cooled to –78 °C in an acetone/anhydrous ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (5.1 mL, 5.10 mmol, 12.5 eq.) was added dropwise under a nitrogen atmosphere. The reaction mixture was allowed to stir for 15 minutes at –78 °C, followed by 16 hours at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). The solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product **7** (67 mg, 61%). ^1H NMR (401 MHz, $\text{DMSO}-d_6$) δ = 11.61 (s, 1H), 11.33 (s, 1H), 10.24 (s, 1H), 9.61 (s, 1H), 8.89–8.64 (m, 1H), 7.79 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 8.4, 2.4 Hz, 1H), 7.08–7.00 (m, 2H), 6.70 (d, J = 2.1 Hz, 1H) ppm. ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ = 164.6, 158.9, 158.5, 156.5, 154.4, 150.6, 146.6, 139.6, 121.6, 116.7, 116.1, 115.3, 114.8, 102.6, 95.2 ppm. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{12}\text{O}_4\text{N}$ [$\text{M} + \text{H}^+$] $^+$ 270.0761, found 270.0760.

3-Methoxynaphthalen-1-ol (9). Naphthalene-1,3-diol (**8**) (1.0 g, 6.25 mmol, 1.0 eq.) was dissolved in anhydrous MeOH (20 mL). The solution was cooled to 0 °C and a 4 M solution of hydrogen chloride in 1,4-dioxane (7 mL, 28.1 mmol, 4.5 eq.) was added to the solution under a nitrogen atmosphere. The reaction mixture was allowed to stir for 16 hours at room temperature until the starting material was consumed (TLC, UPLC-MS). The solvents were evaporated, and oily residues were dissolved in EtOAc (30 mL) and washed with water (3 \times 20 mL) and brine (1 \times 20 mL). The organic phases were dried over anhydrous MgSO_4 . The solvents were evaporated and crude product **9** was used in the next step without further purification (705 mg, 65%). ^1H NMR (401 MHz, CDCl_3) δ = 8.15–8.07 (m, 1H), 7.72–7.68 (m, 1H), 7.46 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.34 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 6.78 (d, J = 2.3 Hz, 1H), 6.55 (d, J = 2.3 Hz, 1H), 3.89 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 157.9, 152.9, 135.6, 127.2, 126.8, 123.1, 121.8, 120.7, 101.5, 99.0, 55.5 ppm. LRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{11}\text{O}_2$ [$\text{M} + \text{H}^+$] $^+$ 175.08, found 175.12.

tert-Butyl((3-methoxynaphthalen-1-yl)oxy)dimethylsilane (10). 3-Methoxynaphthalen-1-ol (**9**) (705 mg, 4.05 mmol, 1.0 eq.)



was dissolved in THF (14 mL), and imidazole (1.38 g, 20.2 mmol, 5.0 eq.) was added. The mixture was cooled to 0 °C, followed by addition of *tert*-butyldimethylsilyl chloride (1.52 g, 10.1 mmol, 2.5 eq.). The reaction mixture was allowed to stir for 2 days at room temperature under a nitrogen atmosphere until the starting material was consumed (TLC, UPLC-MS). A mixture of cyclohexane/EtOAc (1 : 1, 30 mL) was added, and the organic phase was washed with water (1 × 20 mL) and brine (1 × 20 mL). The aqueous phase was extracted with EtOAc (3 × 30 mL). The combined organic phases were dried over anhydrous MgSO₄. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, *n*-hexane/EtOAc = 100:0 → 80:20) to afford the desired compound **10** (529 mg, 45%). ¹H NMR (401 MHz, CDCl₃) δ = 8.08 (dt, *J* = 8.4, 0.7 Hz, 1H), 7.69 (dt, *J* = 8.2, 0.6 Hz, 1H), 7.43 (ddd, *J* = 8.2, 6.8, 1.3 Hz, 1H), 7.31 (ddd, *J* = 8.2, 6.8, 1.2 Hz, 1H), 6.79 (d, *J* = 2.3 Hz, 1H), 6.56 (d, *J* = 2.3 Hz, 1H), 3.90 (s, 3H), 1.10 (s, 9H), 0.30 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 157.9, 152.8, 135.4, 126.8, 126.6, 124.0, 122.9, 122.6, 105.5, 99.1, 55.3, 25.9, 18.5, -4.3 ppm. LRMS (ESI) *m/z* calcd for C₁₇H₂₅O₂Si [M + H]⁺ 289.16, found 289.05.

Miyaura-Ishiyama-Hartwig borylation of 9. A tube with **9** (250 mg, 0.870 mmol, 1.0 eq.), bis(pinacolato)diboron (440 mg, 1.73 mmol, 2.0 eq.), 4,4'-di-*tert*-butyl-2,2'-dipyridyl (14 mg, 0.052 mmol, 0.06 eq.), and bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(i) (23 mg, 0.035 mmol, 0.04 eq.) was sealed, and *n*-hexane (4.8 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes and heated to 100 °C for 16 hours. Then, the reaction mixture was cooled to room temperature, quenched by the addition of water (2.0 mL) and extracted with EtOAc (3 × 20 mL). The combined organic phases were dried over anhydrous MgSO₄. The solvents were evaporated and the residue was purified by flash chromatography (SiO₂, *n*-hexane/EtOAc = 100:0 → 90:10) to afford an inseparable mixture of *tert*-butyl((3-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)oxy)dimethylsilane (**11a**) and *tert*-butyl((3-methoxy-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)oxy)dimethylsilane (**11b**) (345 mg, **11a/11b** = 63:37, 96%). Characterization was performed for the mixture of isomers **11a** and **11b**. ¹H NMR (401 MHz, CDCl₃) δ = 8.64 (dd, *J* = 1.3, 0.7 Hz, 0.47H), 8.22 (t, *J* = 0.9 Hz, 1.00H), 8.10–8.07 (m, 0.43H), 8.05 (d, *J* = 8.3 Hz, 1.00H), 7.77 (dd, *J* = 8.2, 1.2 Hz, 0.41H), 7.68 (dd, *J* = 8.3, 1.2 Hz, 1.13H), 7.67–7.63 (m, 0.61H), 7.42 (ddd, *J* = 8.2, 6.8, 1.3 Hz, 0.41H), 7.31 (ddd, *J* = 8.2, 6.8, 1.2 Hz, 0.41H), 6.87–6.83 (m, 1.00H), 6.80–6.76 (m, 0.92H), 6.59 (d, *J* = 2.3 Hz, 0.99H), 6.55 (dd, *J* = 5.1, 2.3 Hz, 0.94H), 3.90 (s, 2.69H), 3.88 (s, 3.10H), 1.38 (s, 12.00H), 1.36 (s, 6.58H), 1.12 (s, 4.75H), 1.08 (s, 9.35H), 0.30 (s, 2.84H), 0.28 (s, 6.06H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 171.3, 159.0, 158.0, 157.8, 153.6, 152.9, 152.8, 137.3, 135.5, 135.0, 134.8, 131.5, 131.4, 127.8, 126.9, 126.7, 125.8 (2C), 124.1, 123.6, 123.0, 122.7, 121.8, 106.9, 105.9, 105.6, 99.9, 99.3, 99.2, 84.0, 83.7, 60.5, 55.4, 26.0 (4C), 25.1 (4C), 21.2, 18.6 (2C), 14.3, -4.2 (2C) ppm.

6-(3,4-Dihydroxyphenyl)naphthalene-1,3-diol (12). A tube with a mixture of boronates **11a/11b** (ratio: 63:37, 345 mg,

0.83 mmol, 1.5 eq.), 4-bromoveratrole (120 mg, 0.55 mmol, 1.0 eq.), K₂CO₃ (307 mg, 2.22 mmol, 4.0 eq.) and SPhos Pd G2 (40 mg, 0.055 mmol, 0.1 eq.) was sealed, and THF/water (25:1, 5.8 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes, followed by heating to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated and the residue was purified by flash chromatography (SiO₂, *n*-hexane/EtOAc = 100:0 → 80:20) to afford a mixture of *tert*-butyl((6-(3,4-dimethoxyphenyl)-3-methoxynaphthalen-1-yl)oxy)dimethylsilane and *tert*-butyl((7-(3,4-dimethoxyphenyl)-3-methoxynaphthalen-1-yl)oxy)dimethylsilane (194 mg, 82%). The mixture of regioisomers (194 mg, 0.45 mmol, 1.0 eq.) was dissolved in anhydrous THF (1.6 mL). The solution was cooled to 0 °C in an ice water bath, followed by addition of a 1 M solution of tetrabutylammonium fluoride in THF (0.68 mL, 0.68 mmol, 1.5 eq.). The reaction mixture was allowed to stir for 2 hours at 0 °C until the starting material was consumed (UPLC-MS). Then, the solvents were evaporated and the crude product was used in the next step without further purification. The residue was dissolved in anhydrous CH₂Cl₂ (0.7 mL). The solution was cooled to 0 °C in an ice water bath, and a 1 M solution of BBr₃ in CH₂Cl₂ (2.1 mL, 2.1 mmol, 4.7 eq.) was added dropwise under a nitrogen atmosphere. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 2 hours at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). After 30 minutes of stirring, the mixture was lyophilized, and the residue was twice purified by preparative HPLC to afford the desired final product **12** (8 mg, 15%). ¹H NMR (500 MHz, DMSO-*d*₆) δ = 10.03 (s, 1H), 9.45 (s, 1H), 9.05 (s, 1H), 9.00 (s, 1H), 7.95 (d, *J* = 8.7 Hz, 1H), 7.66 (d, *J* = 1.8 Hz, 1H), 7.35 (dd, *J* = 8.7, 1.9 Hz, 1H), 7.12 (d, *J* = 2.2 Hz, 1H), 7.02 (dd, *J* = 8.2, 2.3 Hz, 1H), 6.82 (d, *J* = 8.2 Hz, 1H), 6.62 (d, *J* = 2.1 Hz, 1H), 6.45 (d, *J* = 2.1 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆) δ = 156.2, 154.3, 145.6, 145.2, 138.2, 135.9, 131.7, 122.5, 122.1, 120.1, 118.2, 117.8, 116.0, 114.1, 100.6, 100.4 ppm. HRMS (ESI) *m/z* calcd for C₁₆H₁₁O₄ [M-H]⁻ 267.0663, found 267.0663.

1,6-Dimethoxynaphthalene (14). Naphthalene-1,6-diol (**13**) (2.00 g, 12.5 mmol, 1.0 eq.) was dissolved in anhydrous DMF (20 mL), followed by addition of K₂CO₃ (17.3 g, 125 mmol, 10 eq.) and iodomethane (7.8 mL, 125 mmol, 10 eq.). The reaction mixture was allowed to stir at room temperature overnight until the starting material was consumed (TLC, UPLC-MS). Then, EtOAc (30 mL) was added, and the organic phase was washed with water (3 × 50 mL) and brine (1 × 10 mL) and dried over anhydrous MgSO₄. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, *n*-hexane/EtOAc = 100:0 → 80:20) to afford the desired compound **14** (2.03 g, 86%). ¹H NMR (401 MHz, CDCl₃) δ = 8.22 (d, *J* = 9.1 Hz, 1H), 7.43–7.32 (m, 2H), 7.20–7.12 (m, 2H), 6.71 (dd, *J* = 6.8, 1.9 Hz, 1H), 4.00 (s, 3H),



3.94 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 158.2, 155.8, 136.0, 126.8, 123.8, 120.9, 119.3, 117.6, 105.8, 102.1, 55.5, 55.3 ppm. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{21}\text{O}_4$ [$\text{M} + \text{H}^+$] $^+$ 325.1434, found 325.1433.

2-(4,7-Dimethoxynaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15). A tube with 1,6-dimethoxynaphthalene (**14**) (376 mg, 2.00 mmol, 1.0 eq.), bis(pinacolato)diboron (1.02 g, 4.00 mmol, 2.0 eq.), 4,4'-di-*tert*-butyl-2,2'-dipyridyl (32 mg, 0.12 mmol, 0.06 eq.), and bis(1,5-cyclooctadiene)di- μ -methoxydiiridium(i) (53 mg, 0.08 mmol, 0.04 eq.) was sealed, and *n*-hexane (6.0 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes and heated to 100 °C for 72 hours. Then, the reaction mixture was cooled to room temperature, quenched by the addition of water (2.0 mL) and extracted with EtOAc (3 \times 20 mL). The combined organic phases were dried over anhydrous MgSO_4 . The solvents were evaporated, and the residue was purified by flash chromatography (SiO_2 , *n*-hexane/EtOAc = 100:0 \rightarrow 90:10) to afford the desired boronate **15** (329 mg, 52%). ^1H NMR (401 MHz, CDCl_3) δ = 8.16 (dd, J = 9.9, 0.8 Hz, 1H), 7.88 (s, 1H), 7.20–7.11 (m, 2H), 7.03 (d, J = 0.9 Hz, 1H), 4.03 (s, 3H), 3.90 (s, 3H), 1.39 (s, 12H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 158.1, 155.1, 135.5, 128.0, 123.8, 122.7, 118.8, 106.5, 105.9, 84.0, 55.7, 55.4, 25.1 ppm. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{23}\text{O}_4\text{BNa}$ [$\text{M} + \text{Na}^+$] $^+$ 337.1582, found 337.1580.

3-(3,4-Dimethoxyphenyl)-1,6-dimethoxynaphthalene (16). A tube with boronate **15** (217 mg, 0.69 mmol, 1.5 eq.), 4-bromoveratrole (100 mg, 0.46 mmol, 1.0 eq.), K_2CO_3 (254 mg, 1.84 mmol, 4.0 eq.) and SPhos Pd G2 (33 mg, 0.046 mmol, 0.1 eq.) was sealed, and THF/water (25:1) (5.8 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes, followed by heating to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO_2 , *n*-hexane/EtOAc = 100:0 \rightarrow 80:20) to afford the desired product **16** (81 mg, 54%). ^1H NMR (401 MHz, CDCl_3) δ = 8.18 (d, J = 9.0 Hz, 1H), 7.51–7.46 (m, 1H), 7.28–7.23 (m, 2H), 7.17–7.10 (m, 2H), 6.98 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 1.5 Hz, 1H), 4.05 (s, 3H), 4.00 (s, 3H), 3.95 (s, 3H), 3.93 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 158.6, 156.0, 149.2, 148.8, 139.6, 136.1, 134.8, 123.7, 119.8 (2C), 117.4, 117.0, 111.5, 110.8, 106.0, 102.0, 56.1, 56.0, 55.6, 55.3 ppm. HRMS (APCI) m/z calcd for $\text{C}_{20}\text{H}_{21}\text{O}_4$ [$\text{M} + \text{H}^+$] $^+$ 325.1434, found 325.1433.

3-(3,4-Dihydroxyphenyl)naphthalene-1,6-diol (17). 3-(3,4-Dimethoxyphenyl)-1,6-dimethoxynaphthalene (**16**) (81 mg, 0.25 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (10 mL). The solution was cooled to 0 °C in an ice water bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (2.5 mL, 2.5 mmol, 10 eq.) was added dropwise under a nitrogen atmosphere. Then the reaction mixture was allowed to stir for 15 minutes at 0 °C and then for 2 hours at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). After 30 minutes

of stirring the aqueous phase was extracted with EtOAc (3 \times 25 mL) and the combined organic phases were dried over anhydrous MgSO_4 . The solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product **17** (39 mg, 58%). ^1H NMR (401 MHz, $\text{DMSO}-d_6$) δ = 9.96 (br s, 1H), 9.62 (br s, 1H), 9.02 (br s, 2H), 7.94 (d, J = 9.0 Hz, 1H), 7.25 (br s, 1H), 7.07 (dd, J = 7.0, 2.3 Hz, 2H), 6.96 (td, J = 9.2, 8.7, 2.3 Hz, 2H), 6.86–6.78 (m, 2H) ppm. ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ = 155.9, 153.7, 145.5, 145.1, 138.9, 136.5, 132.1, 123.6, 118.0, 117.8, 116.6, 116.1, 114.1, 113.6, 108.8, 104.3 ppm. HRMS (APCI) m/z calcd for $\text{C}_{16}\text{H}_{13}\text{O}_4$ [$\text{M} + \text{H}^+$] $^+$ 269.0808, found 269.0808.

Methyl 4-acetoxy-5,7-dimethoxy-2-naphthoate (19). A solution of 3,5-dimethoxybenzaldehyde (**18**) (4.00 g, 24.1 mmol, 1.0 eq.) and dimethyl succinate (3.8 mL, 28.9 mmol, 1.2 eq.) in anhydrous *tert*-butanol (12 mL) was added dropwise to a refluxing solution of potassium *tert*-butoxide (4.05 g, 36.1 mmol, 1.5 eq.) in anhydrous *tert*-butanol (24 mL) for 1 hour. Then, the reaction mixture was allowed to stir for 2 hours at 90 °C until the starting material was consumed (UPLC-MS). The solvents were evaporated, the residue was dissolved in 5% HCl (aq., 25 mL), and the aqueous solution was extracted with EtOAc (3 \times 12 mL). The combined organic phases were washed with brine (1 \times 10 mL) and dried over anhydrous MgSO_4 . The solvents were evaporated, a mixture of *n*-hexane/Et₂O (9:1, 25 mL) was added into the oily residue, and the emulsion was vigorously stirred overnight. The crude product containing 4-(3,5-dimethoxyphenyl)-3-(methoxycarbonyl)but-3-enoic acid [(UPLC-ESI): t_R = 4.01 min, m/z calcd for $\text{C}_{14}\text{H}_{15}\text{O}_6$ [$\text{M}-\text{H}^+$] $^-$ 279, found 279] was isolated by decantation of the resulting suspension and used in the next reaction without additional purification. The crude product was suspended in acetic anhydride (35 mL), followed by addition of potassium acetate (3.28 g, 33.5 mmol, 1.5 eq.). The reaction mixture was heated to 145 °C for 6 hours until the starting material was consumed (UPLC-MS, TLC). Then, the reaction mixture was cooled to room temperature, poured into ice (100 mL), and allowed to stir for 30 minutes. The resulting emulsion was extracted with Et₂O (3 \times 150 mL), and the combined organic phases were washed with brine (1 \times 20 mL) and dried over anhydrous MgSO_4 . The solvents were evaporated, and the residue was pre-purified by flash chromatography (SiO_2 , cyclohexane/EtOAc = 100:0 \rightarrow 50:50). The combined fractions containing product were evaporated and purified by recrystallization in EtOH (20 mL) to afford the desired product **19** (1.73 g, 24% over two steps). ^1H NMR (401 MHz, CDCl_3) δ = 8.31 (d, J = 1.7 Hz, 1H), 7.49 (d, J = 1.7 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H), 6.59 (d, J = 2.2 Hz, 1H), 3.94 (s, 3H), 3.90 (s, 6H), 2.36 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 170.0, 166.3, 158.7, 156.1, 146.8, 137.0, 128.3, 127.9, 117.2, 116.6, 101.6, 100.1, 56.1, 55.4, 52.3, 20.9 ppm. LRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{17}\text{O}_6$ [$\text{M} + \text{H}^+$] $^+$ 305.10, found 305.07.

4-Hydroxy-5,7-dimethoxy-2-naphthoic acid (20). Methyl 4-acetoxy-5,7-dimethoxy-2-naphthoate (**19**) (1.73 g, 5.69 mmol, 1.0 eq.) was suspended in 2.5 M NaOH (aq., 34 mL, 85.4



mmol, 15 eq.). The reaction mixture was heated to 100 °C under a nitrogen atmosphere for 2 hours until the starting material was consumed (UPLC-MS). Then, the reaction mixture was cooled to room temperature followed by addition of a concentrated aqueous solution of HCl until pH = 1. The solids were filtered (S3) and purified by recrystallization in EtOH (10 mL) to afford the desired acid **20** (1.31 g, 93%). ¹H NMR (401 MHz, DMSO-*d*₆) δ = 12.90 (br s, 1H), 9.37 (s, 1H), 7.87 (d, *J* = 1.6 Hz, 1H), 7.07–7.02 (m, 2H), 6.69 (d, *J* = 2.3 Hz, 1H), 3.99 (s, 3H), 3.86 (s, 3H) ppm. ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 67.3, 158.2, 157.0, 154.4, 136.6, 129.9, 120.0, 112.5, 107.2, 100.5, 99.7, 56.4, 55.4 ppm. HRMS (ESI) *m/z* calcd for C₁₃H₁₁O₅ [M-H]⁺ 247.0612, found 247.0612.

4,5,7-Trimethoxy-2-naphthoic acid (21). 4-Hydroxy-5,7-dimethoxy-2-naphthoic acid (**20**) (1.37 g, 5.50 mmol, 1.0 eq.) was dissolved in DMF (35 mL), followed by addition of benzyltriethylammonium chloride (125 mg, 0.35 mmol, 0.1 eq.), sodium hydride (60 wt% in mineral oil, 1.65 g, 41.3 mmol, 7.5 eq.) and iodomethane (1.7 mL, 27.5 mmol, 5.0 eq.). The open reaction mixture was allowed to stir at room temperature for 3 days until the starting material was consumed (UPLC-MS). Concentrated hydrochloric acid was slowly added until pH = 1–2, followed by addition of EtOAc (25 mL). The organic phase was washed with water (3 × 75 mL) and brine (1 × 10 mL) and dried over anhydrous MgSO₄. The solvents were evaporated and the crude product was purified by recrystallization in EtOH to afford the desired acid **21** (954 mg, 66%). ¹H NMR (401 MHz, C₅D₅N) δ = 8.61 (d, *J* = 1.5 Hz, 1H), 7.81 (d, *J* = 1.5 Hz, 1H), 7.07 (d, *J* = 2.4 Hz, 1H), 6.82 (d, *J* = 2.3 Hz, 1H), 3.93 (s, 3H), 3.86 (s, 3H), 3.84 (s, 3H) ppm. ¹³C NMR (101 MHz, C₅D₅N) δ = 169.8, 159.7, 159.5, 158.8, 138.7, 131.5, 123.8, 116.2, 104.6, 101.7, 101.0, 56.6, 56.5, 55.8 ppm. HRMS (ESI) *m/z* calcd for C₁₄H₁₃O₅ [M-H]⁺ 261.0769, found 261.0768.

4,4,5,5-Tetramethyl-2-(4,5,7-trimethoxynaphthalen-2-yl)-1,3,2-dioxaborolane (22). A tube with 4,5,7-trimethoxy-2-naphthoic acid (**21**) (262 mg, 1.00 mmol, 1.00 eq.), bis(pinacolato)diboron (381 mg, 1.50 mmol, 1.50 eq.), palladium acetate (12 mg, 0.05 mmol, 0.05 eq.), 1,4-bis(diphenylphosphino)butane (dppb, 43 mg, 0.10 mmol, 0.10 eq.), triethylamine (210 μL, 1.50 mmol, 1.50 eq.), and trimethylacetic anhydride (305 μL, 1.50 mmol, 1.50 eq.) was placed under a positive pressure of argon and subjected to three evacuation/backfilling cycles under high vacuum. Anhydrous 1,4-dioxane (5.0 mL) was added *via* septum, followed by heating to 160 °C for 15 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, diluted with CH₂Cl₂ (10 mL), and filtered through a syringe filter. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 70:30) to afford the desired product **22** (188 mg, 55%). ¹H NMR (401 MHz, CDCl₃) δ = 7.81 (d, *J* = 1.0 Hz, 1H), 7.04 (d, *J* = 1.0 Hz, 1H), 6.77 (d, *J* = 2.4 Hz, 1H), 6.54 (d, *J* = 2.4 Hz, 1H), 4.00 (s, 3H), 3.94 (s, 3H), 3.87 (s, 3H), 1.38 (s, 12H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 185.1, 158.3, 158.0, 156.7, 137.7, 128.5, 115.0, 108.3, 100.0, 99.6, 56.5 (2C),

55.3, 38.7, 27.1 ppm. HRMS (EI) *m/z* calcd for C₁₉H₂₅BO₅ [M]⁺ 344.1790, found 344.1802.

2,2-Dimethyl-5-(4,5,7-trimethoxynaphthalen-2-yl)benzo[d][1,3]dioxole (23). A tube with boronate **22** (100 mg, 0.29 mmol, 1.0 eq.), 5-bromo-2,2-dimethylbenzo[d][1,3]dioxole (80 mg, 0.35 mmol, 1.2 eq.), K₂CO₃ (120 mg, 0.87 mmol, 3.0 eq.) and SPhos Pd G2 (21 mg, 0.029 mmol, 0.1 eq.) was sealed, and THF/water (25:1, 3.0 mL) was added *via* septum. The mixture was degassed by a stream of argon for 15 minutes, followed by heating to 100 °C for 2 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 80:20) to afford the desired product **23** (56 mg, 67%). ¹H NMR (401 MHz, CDCl₃) δ = 7.40 (d, *J* = 1.6 Hz, 1H), 7.14 (dd, *J* = 8.0, 1.8 Hz, 1H), 7.10 (d, *J* = 1.8 Hz, 1H), 6.88 (d, *J* = 1.6 Hz, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.74 (d, *J* = 2.3 Hz, 1H), 6.49 (d, *J* = 2.3 Hz, 1H), 4.01 (s, 3H), 3.96 (s, 3H), 3.91 (s, 3H), 1.73 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 158.6, 158.4, 157.7, 148.1, 147.3, 139.9, 138.5, 135.0, 120.3, 118.3, 117.7, 108.5, 107.7, 104.1, 99.2, 98.8, 60.5, 56.5, 56.4, 55.4, 26.0 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₂₃O₅ [M + H]⁺ 367.1540, found 367.1538.

6-(3,4-Dihydroxyphenyl)naphthalene-1,3,8-triol (carboluteolin) (24). Compound **23** (56 mg, 0.15 mmol, 1.0 eq.) was dissolved in anhydrous CH₂Cl₂ (0.5 mL). The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr₃ in CH₂Cl₂ (2.4 mL, 2.40 mmol, 15.6 eq.) was added dropwise under a nitrogen atmosphere. The reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 1 hour at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (10 mL). The solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product **24** (25 mg, 60%). ¹H NMR (500 MHz, DMSO-*d*₆) δ = 10.69 (s, 1H), 10.67 (s, 1H), 9.54 (br s, 1H), 9.03 (br s, 2H), 7.16 (d, *J* = 1.7 Hz, 1H), 7.05 (d, *J* = 2.2 Hz, 1H), 6.96 (dd, *J* = 8.2, 2.2 Hz, 1H), 6.80 (d, *J* = 8.2 Hz, 1H), 6.65 (d, *J* = 1.7 Hz, 1H), 6.57 (d, *J* = 2.2 Hz, 1H), 6.28 (d, *J* = 2.2 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆) δ = 156.5, 155.2, 154.4, 145.5, 145.3, 139.1, 138.0, 131.4, 117.7, 116.0, 114.0, 113.9, 108.0, 104.1, 101.2, 100.5 ppm. IR (KBr): $\tilde{\nu}$ = 3414(s), 3247(m), 1639(s), 1607(s), 1522(m), 1487(m), 1380(m), 1283(m), 1192(m) cm⁻¹. HRMS (ESI) *m/z* calcd for C₁₆H₁₁O₅ [M-H]⁺ 283.0612, found 283.0609.

2,3-Dimethoxy-5-(4,5,7-trimethoxynaphthalen-2-yl)pyridine (25). Boronate **22** (150 mg, 0.44 mmol, 1.5 eq.), 5-bromo-2,3-dimethoxypyridine (63 mg, 0.29 mmol, 1.0 eq.) and K₂CO₃ (80 mg, 0.58 mmol, 2.0 eq.) were dissolved in 1,4-dioxane/water (3:1, 2.7 mL) in a tube. The mixture was degassed by a stream of argon for 15 minutes, followed by addition of Pd(PPh₃)₄ (35 mg, 0.03 mmol, 0.1 eq.). The tube was sealed and heated to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the



residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 70:30) to afford the desired product **25** (101 mg, 98%). ¹H NMR (401 MHz, CDCl₃) δ = 8.05 (d, *J* = 2.0 Hz, 1H), 7.40 (d, *J* = 1.7 Hz, 1H), 7.34 (d, *J* = 2.0 Hz, 1H), 6.85 (d, *J* = 1.6 Hz, 1H), 6.75 (d, *J* = 2.4 Hz, 1H), 6.51 (d, *J* = 2.3 Hz, 1H), 4.08 (s, 3H), 4.01 (s, 3H), 3.97 (s, 3H), 3.95 (s, 3H), 3.91 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 158.7, 158.4, 158.0, 154.1, 144.1, 138.5, 136.8, 135.4, 130.9, 117.9, 116.6, 112.5, 103.7, 99.1 (2C), 56.6, 56.4, 55.9, 55.4, 54.0 ppm. HRMS (ESI) *m/z* calcd for C₂₀H₂₁O₅NNa [M + Na]⁺ 378.1312, found 378.1310.

2,3-Dimethoxy-6-(4,5,7-trimethoxynaphthalen-2-yl)pyridine (26). Boronate **22** (285 mg, 0.83 mmol, 1.3 eq.), 6-bromo-2,3-dimethoxypyridine (139 mg, 0.64 mmol, 1.0 eq.) and K₂CO₃ (177 mg, 1.28 mmol, 2.0 eq.) were dissolved in 1,4-dioxane/water (3:1, 6.0 mL) in a tube. The mixture was degassed by a stream of argon for 15 minutes, followed by addition of Pd(PPh₃)₄ (74 mg, 0.064 mmol, 0.1 eq.). The tube was sealed and heated to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 70:30) to afford the desired product **26** (83 mg, 37%). ¹H NMR (401 MHz, CDCl₃) δ = 7.86 (d, *J* = 1.6 Hz, 1H), 7.43 (d, *J* = 1.6 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.09 (d, *J* = 8.1 Hz, 1H), 6.79 (d, *J* = 2.3 Hz, 1H), 6.50 (d, *J* = 2.3 Hz, 1H), 4.17 (s, 3H), 4.04 (s, 3H), 3.95 (s, 3H), 3.90 (s, 3H), 3.89 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 158.4, 158.3, 157.6, 153.6, 144.9, 143.5, 138.4, 137.3, 117.8, 117.3, 113.3, 112.9, 102.7, 99.5, 99.0, 56.4, 56.3, 55.9, 55.3, 53.6 ppm. HRMS (ESI) *m/z* calcd for C₂₀H₂₂O₅N [M + H]⁺ 356.1493, found 356.1496.

4,5-Dimethoxy-2-(4,5,7-trimethoxynaphthalen-2-yl)pyridine (27). Boronate **22** (100 mg, 0.29 mmol, 1.5 eq.), 2-bromo-4,5-dimethoxypyridine (42 mg, 0.19 mmol, 1.0 eq.) and K₂CO₃ (53 mg, 0.38 mmol, 2.0 eq.) were dissolved in 1,4-dioxane/water (3:1, 2.0 mL) in a tube. The mixture was degassed by a stream of argon for 15 minutes, followed by addition of Pd(PPh₃)₄ (34 mg, 0.029 mmol, 0.1 eq.). The tube was sealed and heated to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 40:60) to afford the desired product **27** (53 mg, 51%). ¹H NMR (401 MHz, CDCl₃) δ = 8.26 (s, 1H), 7.72 (d, *J* = 1.5 Hz, 1H), 7.40 (d, *J* = 1.5 Hz, 1H), 7.34 (s, 1H), 6.80 (d, *J* = 2.3 Hz, 1H), 6.52 (d, *J* = 2.3 Hz, 1H), 4.06 (s, 3H), 4.03 (s, 3H), 4.00 (s, 3H), 3.95 (s, 3H), 3.90 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 158.5, 158.4, 157.9, 155.7, 152.2, 145.2, 138.3, 138.1, 133.0, 117.8, 113.2, 103.9, 103.0, 99.5, 99.3, 56.8, 56.6, 56.4, 55.9, 55.4 ppm. HRMS (ESI) *m/z* calcd for C₂₀H₂₂O₅N [M + H]⁺ 356.1493, found 356.1489.

2,3-Dimethoxy-5-(4,5,7-trimethoxynaphthalen-2-yl)pyrazine (28). Boronate **22** (100 mg, 0.29 mmol, 1.5 eq.), 5-bromo-2,3-

dimethoxypyrazine (48 mg, 0.19 mmol, 1.0 eq.) and K₂CO₃ (61 mg, 0.44 mmol, 2.0 eq.) were dissolved in 1,4-dioxane/water (3:1, 2.0 mL) in a tube. The mixture was degassed by a stream of argon for 15 minutes, followed by addition of Pd(PPh₃)₄ (26 mg, 0.022 mmol, 0.1 eq.). The tube was sealed and heated to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 60:40) to afford the desired product **28** (51 mg, 65%). ¹H NMR (401 MHz, CDCl₃) δ = 8.19 (s, 1H), 7.83 (d, *J* = 1.6 Hz, 1H), 7.30 (d, *J* = 1.6 Hz, 1H), 6.79 (d, *J* = 2.3 Hz, 1H), 6.51 (d, *J* = 2.3 Hz, 1H), 4.17 (s, 3H), 4.08 (s, 3H), 4.03 (s, 3H), 3.96 (s, 3H), 3.92 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ = 158.6, 158.4, 157.9, 149.7, 149.5, 141.1, 138.4, 135.1, 128.6, 117.4, 114.7, 113.2, 102.3, 99.6, 99.4, 56.5, 56.4, 55.4, 54.3, 53.9 ppm. HRMS (ESI) *m/z* calcd for C₁₉H₂₀O₅N₂Na [M + Na]⁺ 379.1264, found 379.1267.

3,4-Dimethoxy-6-(4,5,7-trimethoxynaphthalen-2-yl)pyridazine (29). Boronate **22** (100 mg, 0.29 mmol, 1.3 eq.), 6-chloro-3,4-dimethoxypyridazine (39 mg, 0.22 mmol, 1.0 eq.) and K₂CO₃ (61 mg, 0.44 mmol, 2.0 eq.) were dissolved in 1,4-dioxane/water (3:1, 2.0 mL) in a tube. The mixture was degassed by a stream of argon for 15 minutes, followed by addition of Pd(PPh₃)₄ (26 mg, 0.022 mmol, 0.1 eq.). The tube was sealed and heated to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂-C₁₈, H₂O (0.1% TFA)/MeCN = 90:10 → 40:60) to afford the desired product **29** (41 mg, 53%). ¹H NMR (401 MHz, C₅D₅N) δ = 8.27 (s, 1H), 8.10 (s, 1H), 7.74 (s, 1H), 6.93 (s, 1H), 6.79 (s, 1H), 4.25 (s, 3H), 4.00 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 3.81 (s, 3H) ppm. ¹³C NMR (101 MHz, C₅D₅N) δ = 159.7 (2C), 159.1, 157.9, 157.0, 149.8, 139.4, 136.8, 119.2, 114.6, 106.4, 103.5, 100.5 (2C), 56.6 (2C), 56.2, 55.8, 55.2 ppm. HRMS (ESI) *m/z* calcd for C₁₉H₂₁O₅N₂ [M + H]⁺ 357.1445, found 357.1448.

4,5-Dimethoxy-2-(4,5,7-trimethoxynaphthalen-2-yl)pyrimidine (30). Boronate **22** (200 mg, 0.58 mmol, 1.3 eq.), 2-chloro-4,5-dimethoxypyrimidine (77 mg, 0.44 mmol, 1.0 eq.) and K₂CO₃ (122 mg, 0.88 mmol, 2.0 eq.) were dissolved in 1,4-dioxane/water (3:1, 4.0 mL) in a tube. The mixture was degassed by a stream of argon for 15 minutes, followed by addition of Pd(PPh₃)₄ (67 mg, 0.058 mmol, 0.1 eq.). The tube was sealed and heated to 100 °C for 16 hours until the starting material was consumed (TLC, UPLC-MS). Then, the reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc. The solvents were evaporated, and the residue was purified by flash chromatography (SiO₂, cyclohexane/EtOAc = 100:0 → 40:60) to afford the desired product **30** (151 mg, 96%). ¹H NMR (401 MHz, CDCl₃) δ = 8.30 (d, *J* = 1.5 Hz, 1H), 8.16 (s, 1H), 7.73 (d, *J* = 1.6 Hz, 1H), 6.85 (d, *J* = 2.3 Hz, 1H), 6.54 (d, *J* = 2.3 Hz, 1H), 4.21 (s, 3H), 4.07 (s, 3H), 3.97 (s, 3H), 3.96 (s,



3H), 3.91 (s, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 159.7, 158.4, 158.3, 157.6, 156.0, 141.3, 138.2, 137.0, 135.9, 119.8, 114.0, 102.9, 100.1, 99.8, 56.5, 56.4 (2C), 55.4, 54.2 ppm. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{21}\text{O}_5\text{N}_2$ $[\text{M} + \text{H}]^+$ 357.1445, found 357.1444.

3-Hydroxy-5-(4,5,7-trihydroxynaphthalen-2-yl)pyridin-2(1H)-one (31). 2,3-Dimethoxy-5-(4,5,7-trimethoxynaphthalen-2-yl)pyridine (25) (101 mg, 0.28 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (1.0 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (5.1 mL, 5.10 mmol, 18 eq.) was added dropwise. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 2 hours at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). The mixture was lyophilized, and the residue was purified by preparative HPLC to afford the desired final product 31 (16 mg, 20%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$, 333 K) δ = 0.66 (br s, 1H), 10.52 (br s, 1H), 7.18–7.16 (m, 2H), 7.11 (d, J = 2.4 Hz, 1H), 6.60 (d, J = 1.7 Hz, 1H), 6.59 (d, J = 2.3 Hz, 1H), 6.32 (d, J = 2.2 Hz, 1H) ppm. ^{13}C NMR (126 MHz, $\text{DMSO}-d_6$, 333 K) δ = 157.5, 156.3, 154.9, 154.4, 146.9, 137.8, 135.1, 121.0, 118.3, 114.4, 113.3, 108.0, 103.0, 101.2, 100.6 ppm. IR (KBr): $\tilde{\nu}$ = 3422(s), 3093(m), 1652(sh), 1616(s), 1496(m), 1456(m), 1383(m), 1313(m), 1237(m), 1195(m) cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{10}\text{O}_5\text{N}$ $[\text{M}-\text{H}]^-$ 284.0565, found 284.0562.

3-Hydroxy-6-(4,5,7-trihydroxynaphthalen-2-yl)pyridin-2(1H)-one (32). 2,3-Dimethoxy-6-(4,5,7-trimethoxynaphthalen-2-yl)pyridine (26) (83 mg, 0.23 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (4.2 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (2.1 mL, 2.10 mmol, 9.0 eq.) was added dropwise. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 48 hours at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). The mixture was lyophilized, and the residue was purified by preparative HPLC to afford the desired final product 32 (36 mg, 53%). ^1H NMR (401 MHz, $\text{DMSO}-d_6$) δ = 11.81 (br s, 1H), 10.90 (s, 1H), 10.69 (s, 1H), 9.67 (br s, 1H), 9.19 (br s, 1H), 7.39 (d, J = 1.7 Hz, 1H), 6.80 (d, J = 7.6 Hz, 1H), 6.70 (d, J = 1.7 Hz, 1H), 6.59 (d, J = 2.2 Hz, 1H), 6.45 (d, J = 7.5 Hz, 1H), 6.36 (d, J = 2.2 Hz, 1H) ppm. ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ = 158.7, 156.7, 155.2, 154.6, 146.5, 137.5, 135.5, 132.1, 116.1, 114.7, 108.9, 104.1, 103.1, 101.8, 101.4 ppm. IR (KBr): $\tilde{\nu}$ = 3418(s), 3051(m), 1646(s), 1609(s), 1496(m), 1383(m), 1275(m), 1194(m), 1007(m) cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{11}\text{O}_5\text{NNa}$ $[\text{M} + \text{Na}]^+$ 308.0529, found 308.0531.

5-Hydroxy-2-(4,5,7-trihydroxynaphthalen-2-yl)pyridin-4(1H)-one (33). 4,5-Dimethoxy-2-(4,5,7-trimethoxynaphthalen-2-yl)pyridine (27) (53 mg, 0.15 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (2.7 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (1.4 mL, 1.40 mmol, 9.0 eq.) was

added dropwise. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 72 hours at room temperature until the starting material was consumed (UPLC-MS). The reaction mixture was poured into a mixture of ice/water (20 mL). The mixture was lyophilized, and the residue was purified by preparative HPLC to afford the desired final product 33 (21 mg, 50%). ^1H NMR (401 MHz, $\text{DMSO}-d_6$) δ = 7.98 (s, 1H), 7.49 (s, 1H), 7.36 (s, 1H), 6.80 (s, 1H), 6.69 (s, 1H), 6.47 (s, 1H) ppm. ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ = 162.6, 157.7, 155.9, 155.8, 145.9, 145.2, 137.8, 131.2, 127.0, 116.9, 110.8, 110.1, 103.4, 102.8, 102.5 ppm. IR (KBr): $\tilde{\nu}$ = 3414(s), 3266(m), 1623(s), 1595(s), 1539(m), 1487(m), 1384(m), 1207(s) cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{10}\text{O}_5\text{N}$ $[\text{M}-\text{H}]^-$ 284.0565, found 284.0560.

3-Hydroxy-6-(4,5,7-trihydroxynaphthalen-2-yl)pyrazin-2(1H)-one (34). 2,3-Dimethoxy-5-(4,5,7-trimethoxynaphthalen-2-yl)pyrazine (28) (91 mg, 0.26 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (5.4 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (2.7 mL, 2.70 mmol, 10.5 eq.) was added dropwise. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 48 hours at room temperature. The reaction mixture was poured into a mixture of ice/water (20 mL). The mixture was lyophilized and dissolved in anhydrous 1,4-dioxane (5.4 mL) followed by addition of a 4 M solution of hydrogen chloride in 1,4-dioxane (5.4 mL, 21.6 mmol, 83.1 eq.). The reaction mixture was heated to 110 °C for 5 hours until the starting material was consumed (UPLC-MS). Then, the solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product 34 (10 mg, 14%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 11.43 (br s, 2H), 9.64 (s, 1H), 7.28 (d, J = 1.7 Hz, 1H), 6.62 (br s, 1H), 6.59 (d, J = 1.8 Hz, 1H), 6.54 (d, J = 2.2 Hz, 1H), 6.33 (d, J = 2.2 Hz, 1H) ppm. ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ = 156.9, 156.7, 155.8, 155.2, 154.7, 137.4, 130.0, 121.8, 113.6, 108.7, 107.1, 102.3, 101.5, 101.1 ppm. IR (KBr): $\tilde{\nu}$ = 3442(s), 3211(m), 1641(sh), 1629(s), 1543(m), 1384(m), 1368(m), 1114(m) cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{10}\text{O}_5\text{N}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 309.0482, found 309.0481.

4-Hydroxy-6-(4,5,7-trihydroxynaphthalen-2-yl)pyridazin-3(2H)-one (35). 3,4-Dimethoxy-6-(4,5,7-trimethoxynaphthalen-2-yl)pyridazine (28) (41 mg, 0.12 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (8.0 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (3.1 mL, 3.1 mmol, 25.8 eq.) was added dropwise. Then, the reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 48 hours at room temperature. The reaction mixture was poured into a mixture of ice/water (20 mL). The mixture was lyophilized and dissolved in anhydrous 1,4-dioxane (0.58 mL), followed by addition of a 4 M solution of hydrogen chloride in 1,4-dioxane (0.6 mL, 2.4 mmol, 20 eq.). Then, the reaction mixture was heated to 110 °C for 5 hours until the starting material was consumed (UPLC-MS). The solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product 35 (7.0 mg, 21%).



^1H NMR (600 MHz, DMSO- d_6) δ = 13.09 (s, 1H), 10.94 (br s, 1H), 10.83 (s, 1H), 10.69 (s, 1H), 9.65 (s, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.27 (s, 1H), 7.00 (d, J = 1.7 Hz, 1H), 6.65 (d, J = 2.2 Hz, 1H), 6.36 (d, J = 2.2 Hz, 1H) ppm. ^{13}C NMR (151 MHz, DMSO- d_6) δ = 157.8, 156.7, 155.3, 154.5, 154.2, 145.8, 137.6, 133.9, 115.3, 109.2, 106.0, 102.3, 101.9, 101.6 ppm. IR (KBr): $\tilde{\nu}$ = 3433(s), 3237(s), 3078(m), 1641(sh), 1635(s), 1534(m), 1468(m), 1392(m), 1368(m), 1238(m) cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_9\text{O}_5\text{N}_2$ $[\text{M}-\text{H}]^-$ 285.0517, found 285.0515.

5-Hydroxy-2-(4,5,7-trihydroxynaphthalen-2-yl)pyrimidin-4(3H)-one (36). 4,5-Dimethoxy-2-(4,5,7-trimethoxynaphthalen-2-yl)pyrimidine (30) (151 mg, 0.42 mmol, 1.0 eq.) was dissolved in anhydrous CH_2Cl_2 (9.0 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C in an ice bath, and a 1 M solution of BBr_3 in CH_2Cl_2 (4.5 mL, 4.5 mmol, 10.7 eq.) was added dropwise. The reaction mixture was allowed to stir for 15 minutes at 0 °C, followed by 24 hours at room temperature. The reaction mixture was poured into a mixture of ice/water (30 mL). The mixture was lyophilized and dissolved in anhydrous 1,4-dioxane (2.1 mL), followed by addition of a 4 M solution of hydrogen chloride in 1,4-dioxane (4.2 mL, 16.8 mmol, 40 eq.). Then, the reaction mixture was heated to 110 °C for 24 hours until the starting material was consumed (UPLC-MS). The solvents were evaporated, and the residue was purified by preparative HPLC to afford the desired final product 36 (32 mg, 27%). ^1H NMR (600 MHz, DMSO- d_6) δ = 12.68 (v b s, 1H), 10.83 (s, 1H), 10.80 (s, 1H), 9.72 (br s, 1H), 9.62 (br s, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.58 (s, 1H), 7.11 (d, J = 1.6 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 6.40 (d, J = 2.2 Hz, 1H) ppm. ^{13}C NMR (151 MHz, DMSO- d_6) δ = 159.0, 156.8, 155.3, 154.4, 148.1*, 143.6, 137.1, 131.5*, 130.8, 116.5, 109.8, 103.3, 102.2, 102.1 ppm. IR (KBr): $\tilde{\nu}$ = 3439(s), 3250(s), 3088(m), 1641(sh), 1627(s), 1596(m), 1538(m), 1483(m), 1366(m), 1270(m) cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{11}\text{O}_5\text{N}_2$ $[\text{M} + \text{H}]^+$ 287.0663, found 287.0665.

4.2 Cloning, expression, and purification of recombinant proteins

DNA encoding the first 196 amino acids of PA-Nter from the A/California/07/2009 (H1N1) strain (GenBank accession no. CY121685.1) with the flexible loop (residues 51–72) replaced by a GGS linker was prepared by GenScript USA Inc.⁶³ The GST–PA-Nter construct was prepared by inserting DNA coding PA-Nter into pGEX-1 λ T. The His₆–SUMO–PA-Nter construct was prepared by cloning DNA encoding PA-Nter with a (GS)₄ linker extension at the N-terminal part into the plasmid pETM11-SUMO3 using *Bam*HI and *Xho*I sites. Both constructs were expressed in *E. coli* BL21 (DE3) RIL cells. Cells were harvested by centrifugation (6000g) and resuspended in lysis buffer [25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA (GST) or 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 10 mM imidazole (His₆–SUMO)] with cOmplete™, EDTA-free protease inhibitor cocktail (Roche). Resuspended cells were lysed with a CF1 cell disruptor (Constant Systems Limited) at a pressure of 15–20 ksi. The soluble proteins expressed from the GST

construct were further purified *via* glutathione agarose and subsequently eluted with a mixture of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM reduced L-glutathione, and 1 mM EDTA. Analogously, His₆–SUMO–PA-Nter was purified by Ni-NTA agarose (Roche) and eluted with a mixture of 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, and 250 mM imidazole. The His₆–SUMO tag was cleaved with ULP1 protease and further eliminated from PA-Nter by Ni-NTA agarose. Both proteins were additionally purified by size exclusion chromatography on a HiLoad Superdex 75 pg column.

4.3 Crystallization and diffraction data collection

To obtain unoccupied crystals of PA-Nter, protein solution (10 mg mL^{-1}) was mixed with crystallization reservoir solution (12.5% (w/v) MDP, 12.5% w/v PEG 1000, 12.5% (w/v) PEG 3350, 0.1 M imidazole/MES monohydrate, pH 6.5, 0.03 M magnesium chloride hexahydrate, 0.03 M calcium chloride dihydrate) and PA-Nter seed in a 1:1:0.2 ratio. Crystals grew in approximately 2 days at 291.14 K and were soaked overnight with 36 in reservoir solution supplemented with 1 mM ligand solution (final 5% DMSO concentration). Crystals were flash-cooled by plunging into liquid nitrogen and were stored in liquid nitrogen.

Diffraction data were collected at 100 K on the MX14.1 beamline at the BESSY II synchrotron, operated by the Helmholtz-Zentrum Berlin, Germany.⁶⁴ Crystals of PA-Nter soaked with 36 (8PPX) diffracted to a resolution of up to 2.5 Å. Diffraction data were processed, integrated, and reduced using XDS⁶⁵ and scaled using XSCALE from the XDS suite.⁶⁶ Crystals belonged to the $P6_422$ space group and contained one molecule in the asymmetric unit, with a solvent content of approximately 47%. Crystal parameters and data collection statistics are given in Table S1.†

4.4 Structure determination and analyses

The structure of PA-Nter in complex with 36 was determined by molecular replacement with MOLREP⁶⁷ from the CCP4 package⁶⁸ using a previously determined PA-Nter structure as a template (PDB entry 6YA5).⁴⁶ The protein structure with ligand was manually built and adjusted in Coot.⁶⁹ Refinement was carried out using REFMAC 8.0.012.⁶⁹ The MolProbity server⁷⁰ was used to evaluate the final model quality. All protein structure figures were prepared with PyMOL (The PyMOL Molecular Graphics System, version 3.0.3 accessed on 1st May 2024; Schrödinger, LLC., New York, NY, USA). Atomic coordinates and structural factors were deposited in the PDB under accession code 8PPX.

4.5 AlphaScreen assay

AlphaScreen experiments were performed using a Perkin Elmer Enspire plate reader in 96-well ProxiPlates. Biotinylated L-742.001 derivative was captured on streptavidin-coated donor beads (Perkin Elmer). Separately, GST–PA-Nter fusion protein was bound to GSH-coated acceptor beads (Perkin Elmer). These solutions were



incubated for 60 min at room temperature in the dark and subsequently mixed and incubated for an additional 120 min. In experiments screening for endonuclease inhibitors, compounds were mixed with both types of beads prior to the 120 min incubation. The optimal concentrations of biotinylated L-742.001 derivative and GST-PA-Nter were 15 nM and 50 nM, respectively. The concentrations of donor and acceptor beads were 5 $\mu\text{g mL}^{-1}$ each in a 50 μL reaction volume. All experiments were performed in AlphaScreen reaction buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween 20, 1 mM MnCl_2 , 10 mM MgCl_2 , and 1 mM 2-mercaptoethanol).

4.6 Anti-influenza A H1N1 California effect of pseudoflavonoid compounds, cytopathic effect (CPE) detection

Anti-influenza A (A/California/07/2009 (H1N1)) activity of selected compounds was tested in MDCK cells (20 000 cells per 100 μL) and A549 cells (25 000 cells per 100 μL) in 96-well plates. Compounds were added to the cells, and after one hour, cells were infected with influenza A (H1N1) (MOI 0.002 for MDCK cells and MOI 0.02 for A549 cells). Infection was carried out in influenza growth medium (DMEM high glucose, no serum, 10 mM HEPES, 0.125% BSA fraction, 1 $\mu\text{g mL}^{-1}$ TPCK-trypsin, penicillin/streptomycin). Cells were incubated for 3 days (MDCK cells) or 4 days (A549) at 37 $^{\circ}\text{C}$, 5% CO_2 . After incubation, CPE was analysed by XTT colorimetric assay. Then, 50 μL of a 50:1 mixture of XTT labelling reagent (1 mg mL^{-1}) and PMS electron-coupling reagent (0.383 mg mL^{-1}) was added to the wells and incubated for 4 hours at 37 $^{\circ}\text{C}$ in 5% CO_2 . Formation of orange formazan dye was measured with an EnVision plate reader. Experiments were performed in biological triplicates, and the resulting data were analysed using GraphPad Prism 9.0 software (GraphPad Software, San Diego, CA, USA).

4.7 Minireplicon assay

All plasmids for the minireplicon assay were kindly provided by Prof. Yoshihiro Kawaoka, University of Wisconsin, Madison, USA. HEK293T cells were seeded in a 96-well plate at a concentration of 3×10^5 cells per well in 100 μL of DMEM complete (10% FBS, penicillin/streptomycin) medium. Alternatively, A549 cells were seeded in a 96-well plate at a concentration of 3×10^5 cells per well in 100 μL of DMEM complete medium. The cells were co-transfected with a set of plasmids encoding the three polymerase subunits and the viral nucleoprotein (pCAGGS-PB1, pCAGGS-PB2, pCAGGS-PA, pCAGGS-NP, all sequences originating from influenza A/WSN/33 H1N1 strain), and with an influenza virus-specific RNA polymerase I-driven firefly luciferase reporter plasmid (pPolI-Flu-ffLuc), using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). To minimize transfection variability, the plasmid pGL4.74 (Promega, Madison, WI, USA) encoding the sequence for *Renilla* luciferase was used as an internal control. Cells were harvested two days after

transfection and incubation with peptides, and luciferase expression was determined using Dual-Glo[®] Luciferase Assay System (Promega, Madison, USA) according to the supplied protocol. The experiments were performed in biological triplicates, and the resulting data were analysed using GraphPad Prism 9.0 software (GraphPad Software, San Diego, CA, USA).

4.8 Cytotoxicity assay

The cytotoxic concentrations that reduced target cell viability by 50% (CC_{50}) were determined by incubating serial dilutions of each test compound and control compounds with the selected cell cultures. HEK 293T, A549 and MDCK cells were seeded at 3×10^3 cells per well in 100 μL DMEM complete medium. The following day, compounds were added to the corresponding wells, and the cells were incubated for 48 hours at 37 $^{\circ}\text{C}$ in 5% CO_2 . After incubation, cell viability was analyzed by XTT colorimetric assay. Then, 50 μL of a 50:1 mixture of XTT labelling reagent (1 mg mL^{-1}) and PMS electron-coupling reagent (0.383 mg mL^{-1}) were added to the wells and incubated for 4 hours at 37 $^{\circ}\text{C}$ in 5% CO_2 . The formation of orange formazan dye was measured on a Tecan Spark plate reader (Tecan Life Sciences, USA). The experiments were performed in biological triplicates, and the resulting data were analyzed using GraphPad Prism 10.0 software (GraphPad Software, San Diego, CA, USA).

Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work the authors used ChatGPT in order to improve the readability and language of the manuscript.

Data availability

The data supporting this article have been included as part of the ESI.†

Author contributions

Róbert Reiberger: investigation. Michal Král: investigation, validation, methodology. Kateřina Radilová: methodology, supervision. Tomáš Kotačka: investigation. Artem Tsaly: investigation. Jiří Brynda: validation, supervision. Pavel Majer: supervision. Jan Konvalinka: writing – review & editing, funding acquisition. Milan Kožíšek: validation, methodology, data curation, writing – original draft, funding acquisition. Aleš Machara: writing – original draft, supervision. Correspondence respective to chemical synthesis should be directed to Dr. Machara. Correspondence respective to evaluations of inhibitory potency of tested compounds should be directed to Dr. Kožíšek.



Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank Prof. Yoshihiro Kawaoka, University of Wisconsin, Madison, USA, for providing plasmids for the minireplicon assay. The project was supported by The Czech National Node to the European Infrastructure for Translational Medicine EATRIS-CZ, grant No. LM2023053, and by the European Union – Next Generation EU – the project National Institute of Virology and Bacteriology (Program EXCELES, ID Project No. LX22NPO5103) and by the Academy of Sciences of the Czech Republic as part of the Strategy AV 21 Virology and Antiviral Therapy program.

Notes and references

- 1 A. D. Iuliano, K. M. Roguski, H. H. Chang, D. J. Muscatello, R. Palekar, S. Tempia, C. Cohen, J. M. Gran, D. Schanzer, B. J. Cowling, P. Wu, J. Kyncl, L. W. Ang, M. Park, M. Redlberger-Fritz, H. J. Yu, L. Espenhain, A. Krishnan, G. Emukule, L. van Asten, S. P. da Silva, S. Aungkulanon, U. Buchholz, M. A. Widdowson, J. S. Bresee, E. Azziz-Baumgartner, P. Y. Cheng, F. Dawood, I. Foppa, S. Olsen, M. Haber, C. Jeffers, C. R. MacIntyre, A. T. Newall, J. G. Wood, M. Kundi, T. PopowKraupp, M. Ahmed, M. Rahman, F. Marinho, C. V. Proschle, N. Mallegas, L. Z. Feng, L. Sa, J. Barbosa-Ramírez, D. M. Sanchez, L. A. Gomez, X. B. Vargas, B. A. Herrera, M. J. Llanés, T. K. Fischer, T. G. Krause, K. Molbak, J. Nielsen, R. Trebbien, A. Bruno, J. Ojeda, H. Ramos, M. an der Heiden, L. D. C. Signor, C. E. Serrano, R. Bhardwaj, M. Chadha, V. Narayan, S. Kosen, M. Bromberg, A. Glatman-Freedman, Z. Kaufman, Y. Arima, K. Oishi, S. Chaves, B. Nyawanda, R. A. Al-Jarallah, P. A. Kuri-Morales, C. R. Matus, M. E. J. Corona, A. Burmaa, O. Darmaa, M. Obtel, I. Cherkaoui, C. C. van den Wijngaard, W. van der Hoek, M. Baker, D. Bandaranayake, A. Bissielo, S. Huang, L. Lopez, C. Newbern, E. Flem, G. M. Groneng, S. Hauge, F. G. de Cosío, Y. de Moltó, L. M. Castillo, M. A. Cabello, M. von Horoch, J. M. Osis, A. Machado, B. Nunes, A. P. Rodrigues, E. Rodrigues, C. Calomfirescu, E. Lupulescu, R. Popescu, O. Popovici, D. Bogdanovic, M. Kostic, K. Lazarevic, Z. Milosevic, B. Tiodorovic, M. Chen, J. Cutter, V. Lee, R. Lin, S. Ma, A. L. Cohen, F. Treurnicht, W. J. Kim, C. D. Sanz, S. D. Ontañón, A. Larrauri, I. León, F. Vallejo, R. Born, C. Junker, D. Koch, J. H. Chuang, W. T. Huang, H. W. Kuo, Y. C. Tsai, K. Bundhamcharoen, M. Chittaganpitch, H. K. Green, R. Pebody, N. Goñi, H. Chiparelli, L. Brammer and D. Mustaquim, *Lancet*, 2018, **391**, 1285–1300.
- 2 A. J. W. te Velhuis and E. Fodor, *Nat. Rev. Microbiol.*, 2016, **14**, 479–493.
- 3 J. T. Zhang, Y. M. Hu, R. Musharrafieh, H. Yin and J. Wang, *Curr. Med. Chem.*, 2019, **26**, 2243–2263.
- 4 Z. X. Zhou, T. Liu, J. Zhang, P. Zhan and X. Y. Liu, *Drug Discovery Today*, 2018, **23**, 503–518.
- 5 T. M. Stubbs and A. J. W. te Velhuis, *Future Virol.*, 2014, **9**, 863–876.
- 6 S. Boivin, S. Cusack, R. W. H. Ruigrok and D. J. Hart, *J. Biol. Chem.*, 2010, **285**, 28411–28417.
- 7 E. J. Mifsud, F. G. Hayden and A. C. Hurt, *Antiviral Res.*, 2019, **169**, 104545.
- 8 S. N. Chen, Z. M. Jiang, Q. C. Li, W. L. Pan, Y. Chen and J. H. Liu, *J. Med. Virol.*, 2024, **96**, e29622.
- 9 K. Hara, F. I. Schmidt, M. Crow and G. G. Brownlee, *J. Virol.*, 2006, **80**, 7789–7798.
- 10 A. Dias, D. Bouvier, T. Crépin, A. A. McCarthy, D. J. Hart, F. Baudin, S. Cusack and R. W. H. Ruigrok, *Nature*, 2009, **458**, 914–918.
- 11 H. Ju, J. Zhang, B. S. Huang, D. W. Kang, B. Huang, X. Y. Liu and P. Zhan, *J. Med. Chem.*, 2017, **60**, 3533–3551.
- 12 Y. Ren, L. Wan and S. Cao, *Mol. Diversity*, 2024, **28**, 1323–1333.
- 13 B. M. Baughman, P. J. Slavish, R. M. DuBois, V. A. Boyd, S. W. White and T. R. Webb, *ACS Chem. Biol.*, 2012, **7**, 526–534.
- 14 A. Y. Chen, R. N. Adamek, B. L. Dick, C. V. Credille, C. N. Morrison and S. M. Cohen, *Chem. Rev.*, 2019, **119**, 1323–1455.
- 15 T. Crépin, A. Dias, A. Palencia, C. Swale, S. Cusack and R. W. H. Ruigrok, *J. Virol.*, 2010, **84**, 9096–9104.
- 16 S. M. Cohen, *Acc. Chem. Res.*, 2017, **50**, 2007–2016.
- 17 C. V. Credille, B. L. Dick, C. N. Morrison, R. W. Stokes, R. N. Adamek, N. C. Wu, I. A. Wilson and S. M. Cohen, *J. Med. Chem.*, 2018, **61**, 10206–10217.
- 18 C. V. Credille, Y. Chen and S. M. Cohen, *J. Med. Chem.*, 2016, **59**, 6444–6454.
- 19 T. Noshi, M. Kitano, K. Taniguchi, A. Yamamoto, S. Omoto, K. Baba, T. Hashimoto, K. Ishida, Y. Kushima, K. Hattori, M. Kawai, R. Yoshida, M. Kobayashi, T. Yoshinaga, A. Sato, M. Okamatsu, Y. Sakoda, H. Kida, T. Shishido and A. Naito, *Antiviral Res.*, 2018, **160**, 109–117.
- 20 Y. A. Heo, *Drugs*, 2018, **78**, 693–697.
- 21 T. Uehara, F. G. Hayden, K. Kawaguchi, S. Omoto, A. C. Hurt, M. D. De Jong, N. Hirotsu, N. Sugaya, N. Lee, K. Baba, T. Shishido, K. Tsuchiya, S. Portsmouth and H. Kida, *J. Infect. Dis.*, 2020, **221**, 346–355.
- 22 M. Imai, M. Yamashita, Y. Sakai-Tagawa, K. Iwatsuki-Horimoto, M. Kiso, J. Murakami, A. Yasuhara, K. Takada, M. Ito, N. Nakajima, K. Takahashi, T. J. S. Lopes, J. Dutta, Z. Khan, D. Kriti, H. van Bakel, A. Tokita, H. Hagiwara, N. Izumida, H. Kuroki, T. Nishino, N. Wada, M. Koga, E. Adachi, D. Jubishi, H. Hasegawa and Y. Kawaoka, *Nat. Microbiol.*, 2020, **5**, 27–33.
- 23 L. Checkmahomed, Z. M'hamdi, J. Carbonneau, M. C. Venable, M. Baz, Y. Abed and G. Boivin, *J. Infect. Dis.*, 2020, **221**, 63–70.
- 24 J. Tomassini, H. Selnick, M. E. Davies, M. E. Armstrong, J. Baldwin, M. Bourgeois, J. Hastings, D. Hazuda, J. Lewis, W. McClements, G. Ponticello, E. Radzilowski, G. Smith, A. Tebben and A. Wolfe, *Antimicrob. Agents Chemother.*, 1994, **38**, 2827–2837.



- 25 J. A. Ruan, K. Y. Lu, J. F. He, Y. H. Chen, B. X. Li, X. Wan, X. Chen, S. M. Li, S. W. Liu and G. P. Song, *Bioorg. Chem.*, 2024, **144**, 107139.
- 26 Y. X. Liao, Y. L. Ye, S. M. Li, Y. L. Zhuang, L. Y. Chen, J. X. Chen, Z. N. Cui, L. J. Huo, S. W. Liu and G. P. Song, *Eur. J. Med. Chem.*, 2020, **189**, 112048.
- 27 J. D. Bauman, D. Patel, S. F. Baker, R. S. K. Vijayan, A. Xiang, A. K. Parhi, L. Martínez-Sobrido, E. J. LaVoie, K. Das and E. Arnold, *ACS Chem. Biol.*, 2013, **8**, 2501–2508.
- 28 C. V. Credille, C. N. Morrison, R. W. Stokes, B. L. Dick, Y. F. Feng, J. X. Sun, Y. Chen and S. M. Cohen, *J. Med. Chem.*, 2019, **62**, 9438–9449.
- 29 M. Miyagawa, T. Akiyama, Y. Taoda, K. Takaya, C. Takahashi-Kageyama, K. Tomita, K. Yasuo, K. Hattori, S. Shano, R. Yoshida, T. Shishido, T. Yoshinaga, A. Sato and M. Kawai, *J. Med. Chem.*, 2019, **62**, 8101–8114.
- 30 H. Y. Sagong, A. Parhi, J. D. Bauman, D. Patel, R. S. K. Vijayan, K. Das, E. Arnold and E. J. LaVoie, *ACS Med. Chem. Lett.*, 2013, **4**, 547–550.
- 31 H. Y. Sagong, J. D. Bauman, A. Nogales, L. Martínez-Sobrido, E. Arnold and E. J. LaVoie, *ChemMedChem*, 2019, **14**, 1204–1223.
- 32 L. Zhang, D. Ke, Y. T. Li, H. Zhang, X. Zhang, S. H. Wang, S. K. Ni, B. Peng, H. X. Zeng, T. J. Hou, Y. S. Du, P. C. Pan, Y. P. Yu and W. T. Chen, *Eur. J. Med. Chem.*, 2024, **276**, 116639.
- 33 E. Kowalinski, C. Zubieta, A. Wolkerstorfer, O. H. J. Szolar, R. W. H. Ruigrok and S. Cusack, *PLoS Pathog.*, 2012, **8**, e1002831.
- 34 T. Kuzuhara, Y. Iwai, H. Takahashi, D. Hatakeyama and N. Echigo, *PLoS Curr.*, 2009, **1**, RRN1052.
- 35 G. Zoidis, E. Giannakopoulou, A. Stevaert, E. Frakolaki, V. Myrianthopoulos, G. Fytas, P. Mavromara, E. Mikros, R. Bartenschlager, N. Vassilaki and L. Naesens, *MedChemComm*, 2016, **7**, 447–456.
- 36 M. Carcelli, D. Rogolino, A. Bacchi, G. Rispoli, E. Fiscaro, C. Compari, M. Sechi, A. Stevaert and L. Naesens, *Mol. Pharmaceutics*, 2014, **11**, 304–316.
- 37 D. Rogolino, L. Naesens, J. Bartoli, M. Carcelli, L. De Luca, G. Pelosi, R. W. Stokes, R. Van Berwaer, S. Vittorio, A. Stevaert and S. M. Cohen, *Bioorg. Chem.*, 2021, **116**, 105388.
- 38 J. C. Jones, B. M. Marathe, C. Lerner, L. Kreis, R. Gasser, P. N. Q. Pascua, I. Najera and E. A. Govorkova, *Antimicrob. Agents Chemother.*, 2016, **60**, 5504–5514.
- 39 J. J. Feng, F. Y. Guo, P. Li, J. Zhang, K. X. Jiang, Z. Z. Zhu, S. S. Yin, X. W. Lin, F. S. Lin, F. B. Xiao, X. X. Xue, H. Y. He and S. H. Chen, *J. Med. Chem.*, 2024, **67**, 2570–2583.
- 40 M. Carcelli, D. Rogolino, A. Gatti, L. De Luca, M. Sechi, G. Kumar, S. W. White, A. Stevaert and L. Naesens, *Sci. Rep.*, 2016, **6**, 31500.
- 41 M. Král', T. Kotačka, R. Reiberger, G. Panýrková, K. Radilová, Z. Osifová, M. Flieger, J. Konvalinka, P. Majer, M. Kožíšek and A. Machara, *ChemMedChem*, 2025, **20**, e202400577.
- 42 V. Zima, K. Radilová, M. Kožíšek, C. B. Albiñana, E. Karlukova, J. Brynda, J. Fanfrlík, M. Flieger, J. Hodek, J. Weber, P. Majer, J. Konvalinka and A. Machara, *Eur. J. Med. Chem.*, 2020, **208**, 112754.
- 43 R. Reiberger, K. Radilová, M. Král', V. Zima, P. Majer, J. Brynda, M. Dračínský, J. Konvalinka, M. Kožíšek and A. Machara, *Int. J. Mol. Sci.*, 2021, **22**, 7735.
- 44 J. Baell and M. A. Walters, *Nature*, 2014, **513**, 481–483.
- 45 J. B. Baell, *J. Nat. Prod.*, 2016, **79**, 616–628.
- 46 V. Zima, K. Radilová, M. Kozísek, C. B. Albiñana, E. Karlukova, J. Brynda, J. Fanfrlík, M. Flieger, J. Hodek, J. Weber, P. Majer, J. Konvalinka and A. Machara, *Eur. J. Med. Chem.*, 2020, **208**, 112754.
- 47 R. Reiberger, K. Radilová, M. Král', V. Zima, P. Majer, J. Brynda, M. Dračínský, J. Konvalinka, M. Kozísek and A. Machara, *Int. J. Mol. Sci.*, 2021, **22**, 7735.
- 48 L. Chen, H. Cao, Q. Huang, J. B. Xiao and H. Teng, *Crit. Rev. Food Sci. Nutr.*, 2022, **62**, 7730–7742.
- 49 S. H. Thilakarathna and H. P. V. Rupasinghe, *Nutrients*, 2013, **5**, 3367–3387.
- 50 D. Del Rio, A. Rodriguez-Mateos, J. P. E. Spencer, M. Tognolini, G. Borges and A. Crozier, *Antioxid. Redox Signaling*, 2013, **18**, 1818–1892.
- 51 G. La Monica, A. Bono, F. Alamia, A. Lauria and A. Martorana, *Bioorg. Med. Chem.*, 2024, **109**, 117791.
- 52 K. Kawara, G. Tsuji, Y. Taniguchi and S. Sasaki, *Chem. – Eur. J.*, 2017, **23**, 1763–1769.
- 53 A. Machara and T. Hudlický, *Targets Heterocycl. Syst.*, 2016, **20**, 113–138.
- 54 J. P. Fischer, J. B. Fell, J. F. Blake, R. J. Hinklin, M. J. Mejia, E. J. Hicken, M. J. Chicarelli, J. J. Gaudino, G. P. A. Vigers, L. E. Burgess, M. A. Marx, J. G. Christensen, M. R. Lee, P. Savechenkov and H. J. Zecca, *WO Pat.*, WO2017201161A1, 2017.
- 55 S. Planken, H. Cheng, M. R. Collins, J. E. Spangler, A. Brooun, A. Maderna, C. Palmer, M. A. Linton, A. Nagata and P. Chen, *US Pat.*, US2019233440A1, 2020.
- 56 K. Suzuki, Y. Tsurumi, K. Kawano, S. Imazeki and T. Murase, *US Pat.*, US2017342031A1, 2017.
- 57 T. Ishiyama, J. Takagi, K. Ishida, N. Miyaura, N. R. Anastasi and J. F. Hartwig, *J. Am. Chem. Soc.*, 2002, **124**, 390–391.
- 58 D. W. Cameron, G. I. Feutrill and L. J. H. Pannan, *Aust. J. Chem.*, 1980, **33**, 2531–2541.
- 59 C. W. Liu, C. L. Ji, X. Hong and M. Szostak, *Angew. Chem., Int. Ed.*, 2018, **57**, 16721–16726.
- 60 H. Y. Sagong, J. D. Bauman, D. Patel, K. Das, E. Arnold and E. J. LaVoie, *J. Med. Chem.*, 2014, **57**, 8086–8098.
- 61 A. Yasgar, A. Jadhav, A. Simeonov and N. P. Coussens, *Methods Mol. Biol.*, 2016, **1439**, 77–98.
- 62 A. K. Parhi, A. Xiang, J. D. Bauman, D. Patel, R. S. K. Vijayan, K. Das, E. Arnold and E. J. LaVoie, *Bioorg. Med. Chem.*, 2013, **21**, 6435–6446.
- 63 R. M. DuBois, P. J. Slavish, B. M. Baughman, M. K. Yun, J. Bao, R. J. Webby, T. R. Webb and S. W. White, *PLoS Pathog.*, 2012, **8**, e1002830.
- 64 U. Mueller, R. Förster, M. Hellmig, F. U. Huschmann, A. Kastner, P. Malecki, S. Pühringer, M. Röwer, K. Sparta, M. Steffien, M. Ühlein, P. Wilk and M. S. Weiss, *Eur. Phys. J. Plus*, 2015, **130**, 141.
- 65 W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 125–132.



- 66 W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 133–144.
- 67 A. Vagin and A. Teplyakov, *J. Appl. Crystallogr.*, 1997, **30**, 1022–1025.
- 68 M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin and K. S. Wilson, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2011, **67**, 235–242.
- 69 P. Emsley and K. Cowtan, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2004, **60**, 2126–2132.
- 70 V. B. Chen, W. B. Arendall, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson and D. C. Richardson, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 12–21.

